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ABSTRACT 
 
FGF signaling is a key pathway strictly involved in many stages of ossification and gain 
of function mutations of many FGF pathway components have been associated with bone 
diseases like craniosynostosis and chondrodysplasia. The fine-tuning of the FGF 
signaling pathway is achieved at different levels, both intracellularly and by extracellular 
glycosaminoglycans (GAGs), which play a critical role in ligand and receptor binding. In 
this work, I show that the deficiency of iduronate 2-sulfatase (IDS), which is involved in 
GAGs catabolism, perturbs FGF signaling leading to early bone defects before the onset 
of evident massive GAGs storage. 
A defective IDS activity causes a rare lysosomal storage disease called 
Mucopolysaccharidosis type II, in which skeletal abnormalities represent one of the major 
disabling aspects. Enzyme replacement therapy (ERT) is the currently available 
therapeutic option, which, however, suffer from limited efficacy. 
To better elucidate early alterations of bone development occurring in MPSII, I took 
advantage of the zebrafish model, given its easy genetic manipulation and the 
evolutionary conserved mechanisms and signaling pathways regulating bone formation. 
In particular, I generated zebrafish models for MPSII, using a morpholino-based knock 
down technology and CRISPR/Cas9 technique, respectively. Using different approaches, 
including in situ hybridization and transgenesis, I demonstrated that the altered IDS 
function affects the expression of key FGF signaling markers and bone differentiation 
markers at early life stages, before any massive glycosaminoglycans accumulation is 
detectable.  
The involvement of the FGF signaling downstream to the IDS loss of function was also 
detected in cranial and appendicular bones of IDS knockout mice and in Hunter patient 
fibroblasts. Therefore, the  results of this study suggest that in MPSII an early FGF 
signaling impairment, due to IDS deficit, may cause a dysregulated expression of genes 
involved in bone development before the occurrence of lysosomal GAGs accumulation. 
 
 
 
 
 
 
 
 
 
 
RIASSUNTO 
 
La via di segnale FGF è una importante pathway coinvolta 
e mutazioni che colpiscono componenti di questa via sono associate a diverse malattie 
umane come le craniosinostosi e le condrodisplasie. La regolazione della via di segnale 
FGF avviene a diversi livelli, sia con meccanismi intracellulari 
con i glicosaminoglicani (GAGs) presenti nella matrice extracellulare, i quali possiedono 
ligando e recettore. 
In questo lavoro o 
2-sulfatasi (IDS), coinvolto nel catabolismo dei GAGs, sono re  
della via di segnale FGF.  
La mancata o deficitaria at  una rara 
patologia da accumulo lisosomiale chiamata Mucopolisaccaridosi di tipo II, nella quale 
uno degli aspetti più disabilitanti è rappresentato da manifestazioni patologiche 
. La terapia comunemente impiegata è la somministrazione 
un miglioramento di una parte della sintomatologia, non risulta efficace, o comunque 
risulta scarsamente efficace, in distretti importanti come cuore e sistema scheletrico.  
Per lo studio della patogenesi molecolare della MPSII e la comprensione dei meccanismi 
patogenetici che inducono alterazioni precoci nello sviluppo osseo, è stato utilizzato lo 
zebrafish come modello. Zebrafish risulta infatti un buon modello perché semplice da 
manipolare geneticamente; inoltre, in esso, il controllo delle principali vie di segnale che 
regolano il suo sviluppo osseo è altamente conservato. 
un mutante stabile applicando il metodo Crispr/Cas9. Utilizzando diversi approcci 
sperimentali, comprese tecniche di ibridazione in situ e transgenesi, è stato dimostrato che 
la mancata   
chiave della via di segnale FGF e della differenziazione ossea a stadi molto precoci, 
prima di un evidente accumulo di glicosaminoglicani nei tessuti.  
azione di questa pathway è stata osservata anche in campioni di ossa craniche e 
appendicolari di topi IDS-KO e in fibroblasti di pazienti Hunter. 
I risultati di questo studio suggeriscono dunque che nella MPSII di
IDS inducano, in fasi precoci, alterazioni nella regolazione della via di segnale FGF, che 
a loro 
sviluppo osseo, prima che si verifichi ei GAGs nei lisosomi. 
 
 
ABBREVIATIONS 
 
4S: N-actylgalactosamine-4-sulfatase 
ASA: Arylsulfatase A 
B2M: beta-2-microglobulin 
BGLAP: Bone Gamma-Carboxyglutamate Protein 
BMPs: Bone morphogenic proteins 
BSP: Bone sialoprotein 
Cas: CRISPR associated proteins 
CNS: Central nervous system 
Col2: collagen II 
ColX: collagen X 
CRISPR: Clustered regularly interspaced short palindromic repeats 
crRNA: CRISPR RNA 
CS: chondroitin sulfate 
dpf: days post fertilization  
DS: dermatan sulfate 
Dusp6: dual specificity phosphatase 6 
ECM: Extracellular matrix 
ENU: N-ethyl-N-nitrosourea 
Erk: Extracellular signal-regulated kinase 
ERM: ETS-related molecule  
ERT: Enzyme Replacement Theraphy 
FGE: FGly generating enzymes 
FGF: Fibroblast growth factor 
FGFr: Fibroblast growth factor receptor 
FGly: Formyglycine 
GAG: Glicosaminoglycan 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
gRNA: guide RNA 
HS: Heparan sulfate 
HSCT: Hematopoietic Stem Cells Transplantation 
ids: iduronate 2-sulfatase gene 
IDS: Iduronate 2-sulfatase enzyme 
IDSP1: iduronate 2-sulfatase pseudo gene 
IHH: Indian hedgehog 
IL1 : interluchine 1  
ISH: in situ hybridization 
KS: keratan sulfate 
LSD: Lysosomal Storage Disorder 
MAP: Mitogen-Activating Protein 
MPS: Mucopolysaccharidosis 
NCC: cranial neural crest 
NHEJ: Non-Homologous End Joining 
nls: nuclear localization signals 
OCN: Osteocalcin 
Osx: Osterix 
PAM: Protospacer Adjacent Motif 
Pea3: Polyoma enhanceractivator 3 
PI3: Phosphoinositide 3 
PLC : Phospholipase C gamma 
PPR: Parathyroid hormone related peptide receptor 
PTC: Patched 
PTHrP: Parathyroid hormone related peptide 
PTU: Phenylthiourea 
Runx: Runt domain-containing transcription factor 
SMO: Smoothened 
Spry: Protein sprouty homolog 
 
tracrRNA: transacting RNA 
WT: wild type 
1 INTRODUCTION 
 
 
1.1 Lysosomal storage disorders 
 
Lysosomal storage disorders (LSDs) are a family of hereditary diseases caused by 
abnormal accumulation of macromolecules into lysosomes, leading to impaired organelle 
homeostasis. More than 50 different LSDs have been classified and their overall 
incidence is almost 1 to 5000 live births (Wraith, 2011).  
Most LSDs are inherited in an autosomal recessive way, while there are only three LSDs 
with an X-linked inheritance: Fabry disease, Danon disease and Mucopolysaccharidosis 
type II. 
LSDs are due to different mutations occurring in genes encoding for lysosomal enzymes 
or proteins important in lysosomal biogenesis or trafficking. The loss of lysosomal 
protein function or enzymatic activity is responsible for a progressive accumulation of 
different kind of substrates (Boustany et al., 2013). Traditionally, LSDs are classified 
according to the type of substrate. However, in most lysosomal storage disorders the 
stored material can be heterogeneous (Ballabio et al., 2009).  
LSDs are generally divided into: 
-Sphingolipidoses 
-Mucopolysaccharidoses  
-Glycogen storage disease 
-Oligosaccharidoses 
-Integral membrane protein disorders. 
Although lysosomal storage disorders can share common basic pathogenetic defects, 
among different LSDs there is a high phenotypic variability, depending on the different  
stored substrates, affected cell types and organ involvement. 
All LSDs display a marked phenotypic heterogeneity, considering the onset of symptoms, 
which can be during pregnancy, at postnatal stages or in late adulthood. Also the 
progression is variable and patients affected by the same LSD or carrying  the same 
disease-related-mutations can display very different disease manifestations (Wraith et al., 
2011). 
The most recurrent pathological alterations in LSDs are dimorphism, cardiac disease, 
hepatosplenomegaly, skeletal disease with dysostosis multiplex and neurological 
abnormalities.  
 
 
1.2 Mucopolysaccharidosis 
 
Mucopolysaccharidoses (MPSs) are an heterogeneous group of rare genetic disorders 
caused by the deficiency of specific lysosomal enzymes that are involved in the 
breakdown of glycosaminoglycans (GAGs) dermatan sulfate (DS), heparan sulfate (HS), 
keratan sulfate (KS), chondroitin sulfate (CS) or hyaluronan. In these disorders the direct 
effect of mutations occurring in lysosomal-related genes is the progressive accumulation 
of undegraded or partially degraded GAGs into the lysosomes. Glycosaminoglycans 
storage leads to progressive cell dysfunction, that in turn causes multiorgan and 
multisystem defects, thus reducing life expectancy. 
There are eleven different types of MPSs that are categorized by the specific altered 
enzyme and the types of stored molecules (Table 1) and their overall incidence is 1 every 
25.000 live births et al., 2016). 
MPSII is the only mucopolysaccharidosis with an X-linked inheritance. The other 
mucopolysaccharidoses are inherited in an autosomal recessive manner and there are no 
differences in their frequency between males and females. All MPSs present with very 
different pathological features, which can be characterized by a variable degree of  
severity. However, some clinical features, such as musculo-skeletal alterations, are 
common to all MPSs. 
Historically, the pathogenesis of MPSs has been attributed to the progressive intracellular 
accumulation of undegraded glycosaminoglycans, however it is now clear that more 
complex pathogenic mechanisms may contribute to the pathological manifestations. 
MPS animal models show that the progressive worsening of symptoms is not associated 
with a progressive tissue GAGs accumulation. Furthermore, in MPSI mouse models it has 
been demonstrated that alterations in the skeletal development occur very early, before 
any histological change (Heppner et al., 2015). 
Since glycosaminoglycans are involved in key cell regulations, such as signal 
transduction and growth factors sequestering, undegraded or partially degraded GAGs 
may lead to cellular homeostasis perturbations, thus deregulating important signaling 
pathways (Clarke et al., 2011). 
 
 
 
 
 
 
 
 
Number Eponym 
Gene 
locus 
Deficient enzyme Storage product 
I Hurler/Scheie 4p16.3 -L-iduronidare Heparan sulfate / Dermatan sulfate 
II Hunter Xq28 Iduronate 2-sulfatase Heparan sulfate / Dermatan sulfate 
III-A Sanfilippo type A 17q25.3 Sulfamidase Heparan sulfate 
III-B Sanfilippo type B 17q21 -N-acetylglucosamidase Heparan sulfate 
III-C Sanfilippo type C 8p11.1 
Acetyl-CoA; -
glucosamidase N-
acetyltransferase 
Heparan sulfate 
III-D Sanfilippo type D 12q14 N-acetylglucosamidase 6-sulfatase Heparan sulfate 
IV-A Morquio type A 16q24.3 Galactose 6-sulfatase Keratan sulfate / Chondroitin sulfate 
IV-B Morquio type B 3p21.33 -galactosidase Keratan sulfate 
VI Maroteaux-Lamy 5q11-q13 Arylsulfatase B 
Heparan sulfate / 
Dermatan sulfate 
VII Sly 7q21.11 -glucuronidase 
Heparan sulfate / 
Dermatan sulfate / 
Chondroitin sulfate 
IX  3p21.3-p21.2 Hyaluronidase Hyaluronan 
Table 1: List of all MPS types with their eponym. For each Mucopolysaccaridosis is 
described the gene locus, the enzyme deficit and the storage product. 
 
 
1.3 Mucopolysaccharidosis type II  
 
Mucopolysaccharidosis type II, also called Hunter syndrome, is caused by the lack or 
deficiency of the lysosomal enzyme iduronate 2-sulfatase (IDS, EC 3.1.6.13). IDS is a 
glycosidase required for the hydrolysis of the 2-sulfate groups of L-iduronate 2-sulfate 
units, the first step of heparan sulfate and dermatan sulfate degradative pathway. The 
enzyme acts into the lysosomes and mutations altering its function lead to GAGs 
accumulation within the lysosomes in nearly all cell types.  
The prevalence of this disease in Caucasian population ranges from 1:46.000 to 
1:320.000 live births and it is twice higher in Ashkenazi and Sephardic Jews living in 
Israel (Chistiakov et al., 2014). Since MPSII follows an X-linked recessive inheritance, 
the vast majority of affected individuals are males. However, there are few cases of 
female patients. Most female cases of Hunter syndrome are due to an autosomal-X-
chromosomal translocation or nonrandom X-chromosome inactivation (Morini et al., 
2010). 
Generally, it is possible to recognize 3 pathological phenotypes, according to the age of 
onset, disease severity and rate of progression:   
Severe form: the disease has an early onset with a rapid symptom worsening and the 
diagnosis is usually completed at 3 years of age. Patients are affected by profound mental 
retardation, early dysostosis multiplex, marked somatic changes and multi-organ 
involvement. They present a short life expectancy with death that occurs before 15 years 
of age, usually because of obstructive airway disease or cardiac failure. 
Mild form: the disease has a late onset with delayed symptoms progression and diagnosis 
is usually completed around 10 years of age. Patients have mild or no mental retardation, 
stature is close to normal, while dysostosis and dysmorphism are only slowly progressive. 
Affected patients survive into adulthood with life expectancy of forty or fifty years and 
death may occur by cardiac failure. 
Intermediate form: the disease has a late onset and slow progression. Patients present with 
a wide range of pathological manifestations, which lie between the mild and severe 
forms.  
However, since MPSII is a very complex disease with high symptoms variability, there is 
no strict separation between the three forms and patients often show a continuum of 
pathological manifestations from the severe to the mild forms.  
MPSII patients show impaired growth speed during their life, with an increased weight 
and height compared to unaffected controls at birth, from the first year onwards, the 
growth speed falls down and patients display a block in the development. There are no 
differences in the growth rate between patients with the severe and the mild forms and a 
short stature is the most typical feature in MPSII patients (Patel et al., 2015). 
Patients appear normal at birth and the first clinical features emerge at 2 to 4 years of age 
and have a chronic progressive course. Lysosomal accumulation affects multiple organs 
and multiple systems with a wide range of pathological manifestations. 
The clinical spectrum involves the following organs and tissues: 
Central Nervous system (CNS): CNS involvement is a typical pathological feature of 
the severe forms and defines the neuronopathic type. Patients with CNS involvement 
present a progressive decline in intellectual functions with learning difficulties and a 
progressive neurological decline. Typical pathological manifestations are hydrocephalus, 
spinal cord compression, cerebral infarction and mental retardation (Al Sawaf et al., 
2008). 
Cardiovascular system: Heart dysfunction is a common feature in Hunter syndrome and 
is a contributing factor in the cause of death in both severe and mild forms. GAGs 
deposition in heart tissues leads to defects in cardiac structure that in turn causes the 
organ dysfunction. 
Most patients show progressive valve thickening; other pathological manifestations 
include valvular regurgitation, valvular stenosis and cardiac hypertrophy (Lin et al., 
2014).  
Airway and respiratory: Airway obstruction and heart failure are the most common 
causes of death in MPSII, particularly in young patients (Giugliani et al., 2010). 
GAGs accumulation in oropharyngeal and tracheo-bronchial tracts cause macroglossia, 
supraglottic narrowing and tracheomalacia. The respiratory system is also altered by 
pulmonary restriction due to the enlargement of internal organs and the rib cage rigidity, 
that generates riduced space for the lungs. Furthermore, respiratory alterations frequently 
induce some pathological complications, such as recurrent respiratory infections and 
sleep apnea (Wraith et al., 2008). 
Sensory system: Patients present retinal dystrophy that causes defects in peripheral 
vision and poor dark adaptation. Other eye pathological features are papilledema and 
optic nerve atrophy. Hearing loss is also frequent and most patients exhibit recurrent otitis 
(Wraith et al., 2008). 
Gastrointestinal: Storage of GAGs leads to increased organ size. In fact, hepatomegaly 
and splenomegaly are very common. Patients show protuberances of the abdomen due to 
umbilical and inguinal hernias. 
Skeletal: Patients display several bone defects, including craniosynostosis, which will be 
deeply mentioned in the following paragraph. 
 
 
1.4 Skeletal system alterations in Hunter syndrome 
 
Skeletal abnormalities occur early in Hunter syndrome and are one of the main 
pathological features in all MPSs. Patients display defects in both endochondral and 
intramembranous ossification, that lead to a large spectrum of different pathological 
manifestations. Bones and cartilages in patients are characterized by altered growth and 
defects in shape and structure causing functional abnormalities (Clarke et al., 2015).  
MPS patients show a characteristic pattern of bone alterations, called dysostosis 
multiplex, that can be detected with radiological analysis (Fig. 1). 
The skull has an increased size and patients suffer from prematurely closed calvarial 
thickened sutures and a characteristic J-shape of the sella turcica. The ribs are thickened 
and assume a particular oar-like shape, which is characterized by an anterior enlargement 
and a posterior thinning. The clavicles have an altered shape, are short and broad. The 
spine shows dorsal kyphosis, hypoplasia of the lumbar vertebrae and some patients 
affected by the severe form also present with scoliosis. The pelvis has flaring of iliac 
wings, coxa-valga deformity and dysplastic femoral heads. The hands have a claw-like 
appearance, with bullet shaped phalanges and proximal pointing of metacarpals. Long 
bones are short with enlarged diaphysis, altered epiphyseal centers and irregular 
metaphyseal appearance (Aldenhoven et al., 2009).  
 
Figure 1: Dysostosis multiplex in Mucopolysaccharidosis type II. (A) Enlarged J-shaped 
sella turcica; (B) Pelvis is not well-formed and displays a small femoral head; (C) 
Diaphyseal thickening of lower extremity; (D) Lumbar spine with mild beacking of L1, 
L2 and L3; (E) Chest with calvarial thickening and oar-shaped ribs; (F) Irregular 
metaphyseal appearance. Images modified from (Muenzer et al., 2004) and (Morini et al., 
2010). 
 
es show GAGs storage in all 
cells involved in ossification and bone remodeling: osteoblasts, osteoclasts and osteocytes 
(Polgreen et al., 2014). Glycosaminoglycans interact with several molecules involved in 
physiological and pathological processes, and their abnormally increased levels give rise 
to different cellular responses: metabolic, inflammatory and immunological. 
Inflammatory pathways are activated by the increased expression of IL-
cytokines, leading to altered processes in bone and cartilage development. These 
cytokines induce enzymes that degrade ECM components, stimulate osteoclastic bone 
resorption, inducing RANKL expression, and increase chondrocytes apoptosis (Fig. 2) 
(Opoka-Winiarska et al., 2013).  
 
Figure 2: Metabolic inflammation in MPS diseases (Opoka-Winiarska et al., 2013). 
 
 
1.5 Diagnosis and treatment 
 
The first diagnosis is performed by clinicians that evaluate patient family history and 
symptoms. However, since Hunter syndrome is a rare disease and patients present a wide 
spectrum of different clinical presentations with variable severity, diagnosis is frequently 
misunderstood and delayed. 
GAGs urinary assay is the first screening usually performed when an MPS disease is 
suspected. This assay is used to detect and quantify the stored glycosaminoglycans, but it 
does not give a definitive diagnosis. The final MPSII diagnosis is given by an enzymatic 
assay performed in leukocytes, fibroblasts or plasma, using an iduronate 2-sulfatase 
specific substrate. If there is a familial case of Hunter syndrome
prenatal diagnosis using the enzymatic assay in uncultured chorionic villi (Wraith et al., 
2008).  
The currently available therapies for MPSII are based upon Enzyme Replacement 
Therapy (ERT) and Hematopoietic Stem Cells Transplantation (HSCT).  
ERT therapy consists in the weekly intravenous injection of an iduronate 2-sulfatase 
recombinant enzyme carrying high levels of Mannose 6-phosphate. Treated patients show 
a general reduction of GAGs amount in tissues and urine, a progressive normalization of 
the liver and spleen volumes and an improved respiratory function. However, the drug 
-brain barrier, so it has no efficacy in the treatment of CNS-related 
symptoms. There is also a limited drug delivery of the recombinant enzyme in the cardiac 
valves and hard tissues, such as bone. 
HSCT is based upon the delivery of marrow-derived donor cells that provide a continuous 
source of secreted enzyme. Early administration of HSCT permits to block disease 
progression and improves some pathological features. HSCT is not able to recover Hunter 
syndrome-related bone abnormalities due to the limited enzymatic delivery in the 
skeletal-muscle tissue. Together with ERT or HSCT, patients have to be treated also with 
supportive symptomatic treatments to improve their life quality (Wraith et al., 2008). 
The response to treatments depends on the disease severity and the age at which the 
treatment begins. It is now clear that the time in which therapies start is essential for the 
therapeutic outcome. If the treatment starts before or at the beginning of pathological 
manifestations, the therapy is extremely more successful. One of the main problems in 
therapies of MPS-related skeletal defects is that the treatment usually starts when an 
irreversible bone damage has already occurred, so the treatment can only slow the disease 
progression. 
ERT and HSCT can reduce the burden of GAGs storage and slow down the progression 
of organ and tissue damage caused by the disease, but in some tissues, such as CNS and 
skeletal tissues, they are completely ineffective (Morini et al., 2010). 
 
 
1.6 Genetics 
 
Iduronate 2 sulfatase gene (IDS) maps to X chromosome, at Xq28.1. This gene spans 
approximatively 24kb and it contains nine exons and eight introns. It has been completely 
sequenced, leading to the characterization of the open reading frame composed of 1650bp 
and encoding for a 550 aminoacid protein. 
A pseudogene (IDSP1), located at 
gene, has been identified. The pseudogene contains copies of  exon 2, exon 3 and introns 
2, 3 and 7 of the functional gene and it has  95% of similarity with the functional regions 
(Chistiakov et al., 2014). 
More than 300 different disease-causing mutations have been identified, however 
genotype-phenotype correlation is still lacking. Most variants are point mutations in 
particular missense (44%), non-sense (10%) or splice-site alterations (9%). Small 
insertion/deletion represent 26% of all mutations, while the remaining 11% are large 
deletions, insertions, duplications or rearrangements between the IDS locus and the 
pseudogene (Lualdi et al., 2006). 
Generally, full deletions and gross rearrangements have been associated with a severe 
clinical presentation, however, it has been described a case of a large deletion 
encompassing exons 2-4 that causes an intermediate form of the pathology (Bonuccelli et 
al., 1998). Patients displaying the mild form of MPSII, due to non-sense mutations very 
close to the N-terminal or frameshift mutations that produce a non active small 
polypeptide, have been identified (Kato et al., 2005). Patients, carrying other types of IDS 
gene mutations, have a variable spectrum of defects ranging from the severe to the mild 
forms. 
However, in all patients the enzymatic activity assay, is unable to allow correlation 
between  disease severity and enzymatic function . 
 
 
1.7 Iduronate 2-sulfatase enzyme 
 
IDS is a sulfatase that catalyzes the hydrolysis of sulfate ester bond in position 2 from the 
glycosaminoglycans heparan and dermatan sulfate. It is an housekeeping enzyme located 
into lysosomes, where it performs its optimal activity. IDS is synthesized as two 
precursor forms of 90kDa and 76kDa and successively modified with the adding of 
Mannose 6-Phosphate that targets the enzyme to the lysosomal compartment. IDS then 
 
 yet, but it shows approximatively 20% of homology 
with other enzymes of the sulfatase family. A structural model of the human IDS has 
been created using the homology with the crystal structure of human N-
actylgalactosamine-4-sulfatase (4S) and Arylsulfatase A (ASA) (Fig. 3). This predicted 
tertiary structure has revealed that putative residues in the active site are Asp45, Asp46, 
Cys84, Lys135 and Asp334, which are also highly evolutionary conserved. One of the 
most important aminoacidic residue, located in the active site of the enzyme in humans, is 
the Cystein84, which is transformed into Formylglycine (FGly) residue by FGly 
generating enzymes (FGE) with a post translational oxidation (Sukegawa-Hayasaka et al., 
2006). 
 
Human IDS has a high percent identity with the zebrafish (59,51%) and mouse (79,52%) 
orthologues. Zebrafish Ids is formed by 561 aminoacids and the active Cysteine residue is 
in the 78th aminoacidic position, while mouse IDS is composed of 552 aminoacids and 
the active Cysteine residue is in the 99th aminoacidic position. 
Recently, it has been demonstrated that IDS, beyond its GAGs degradative role, may 
have other important molecular functions. It has been shown that zebrafish iduronate 2-
sulfatase has an important role during early development (Moro et al., 2010). In 
particular, Ids deficiency causes in zebrafish an altered expression of important 
osteogenesis factors, such as Sox10, which is a marker of early differentiating neural crest 
precursors into chondroblasts. Moreover, in agreement with the same observations it has 
been shown that iduronate 2-sulfatase increases its expression during the 
transdifferentiation from mouse fibroblasts to osteoblasts (Mandal et al., 2013). 
 
 
1.8 Lysosome 
 
Lysosomes are the degradative organelles of the endosomal/lysosomal system that take 
part to endocytic, phagocytic and autophagic pathways. They mediate the internalization, 
recycling, transport and breakdown of cellular and extracellular components and facilitate 
the dissociation of receptors from their ligands. 
Being one of the major homeostasis regulators, lysosomes are involved in many cellular 
processes: turnover of cellular components, recycling of cell membrane receptors, 
inactivation of pathogenic organisms, repair of plasma membrane and bone remodeling 
(Settembre et al., 2013). 
Lysosomes are ubiquitously membrane-bound organelle with an acidic lumen of pH 4.5 
and contain more than 60 different enzymes involved in the degradation of specific 
substrates. Lysosomes are delimited by a single-lipid bilayer membrane that is protected 
by a thick internal glycocalyx from the acidic environment of the lumen. 
Figure 3: Tertiary structure model of 
Iduronate 2-sulfatase. The spheres 
indicates active site residues: Asp45, 
Asp46, Cys84, Arg88, Lys135 and 
Asp334 (Chkioua et al., 2011).  
Extracellular materials reach the lysosomes through the endocytic pathway, whereas 
intracellular components enter the lysosomes through autophagy. 
The endocytic pathway allows the internalization of extracellular molecules that need to 
be degraded into lysosomes through cell surface receptors or in the case of hydrophobic 
small molecules by passive diffusion. Digested materials and receptors can return to the 
cell membrane via the recycling endosomes (Appelqvist et al., 2013).  
Lysosomes also participate in lysosomal exocytosis, that is a secretory pathway important 
for some processes such as immune responses, bone resorption, cell signaling and plasma 
membrane repair (Appelqvist et al., 2013).  
 
 
1.9 Extracellular matrix 
 
The extracellular matrix (ECM) is a highly dynamic structure surrounding cells and 
regulating many asp
collagens, proteoglycans, glycoproteins and elastin that bestow physical and biochemical 
ECM properties. It presents with a high level of organization with a well-defined quantity 
and distribution of structural components, which interact in a determinate manner to 
provide specific mechanical and physiological features (Tsang et al., 2010).  
ECM is subjected to remodeling, to regulate different processes during development and 
maintain cell homeostasis. It has an intimate connection with cells and, through its 
constant remodeling, it modulates the transduction of signaling molecules that regulate 
differentiation, proliferation and cell death. The ECM regulation occurs by changes in its 
composition, and modification of its architecture (Lu et al., 2011). The following 
properties are characteristic of the extracellular matrix (Fig. 4) (Lu et al., 2011): 
-Anchorage: through ECM, receptors can help to maintain cell polarity, tissue 
organization and cell function. 
-Migration barrier: the ECM constitutes a barrier for migrating cells that could be more 
permissive by regulation of spatial and temporal ECM composition. 
-Migrating track: ECM can promote cell movements, by influencing the direction of 
migration and providing force for the movement. 
-Signal reservoir: ECM components can bind grow factors and ligands by assembling 
them in a limited space, creating a concentration gradient and simplifying their interaction 
with receptors. 
-Low affinity coreceptor: ECM components can enhance the interaction between 
receptors and ligands. For example, heparan sulfate is necessary for the dimerization and 
activation of FGF receptor after the binding with FGF ligands.  
-Signal presenter: ECM components can participate in signal transduction acting as 
endogenous grow factors and activating directly the signaling. 
-Biochemical force: the matrix can change its biochemical properties by determining cell 
behavior and regulating the development. ECM rigidity or stiffness can influence cellular 
differentiation and stem cell lineage specification. 
 
. 
Figure 4: Representation of all the functional and structural properties of the extracellular 
matrix. The image is taken from (Lu et al., 2011). 
 
 
1.10 Development of vertebrate skeleton 
 
Bone development is a temporally and spatially regulated complex process based upon 
the expression of extracellular matrix components, transcription factors, growth factors 
and hormones.  
The first event is the condensation and differentiation of mesenchymal progenitor cells 
from neural crest cells, that give rise to the craniofacial skeleton, and from the lateral 
plate of mesoderm, that gives rise to appendicular skeleton (Aszódi et al., 2000).  
There are two bone developmental mechanisms: intramembranous ossification and 
endochondral ossification. 
During intramembranous ossification, mesenchymal stem cells differentiate directly into 
osteoblasts and lead to the development of skull flat bones and most of the facial 
skeleton.  
By endochondral ossification, mesenchymal progenitor cells generate a cartilaginous 
template that is progressively replaced by bone and gives rise to long bones, vertebrae 
and ribs. The initial cartilage is avascular and it is composed of chondrocytes, while at the 
periphery there are proliferating cells that form the perichondrium. Chondrocytes 
differentiate into hypertrophic chondrocytes that are surrounded by mineralized matrix 
produced by osteoblasts derived from perichondrium osteoprogenitor cells. In this phase 
blood vessel invade the region and the growing capillaries transport mesenchymal cells 
that differentiate into osteoblasts and chondroclasts (Aszódi et al., 2000).  
Long bones are characterized by a primary ossification center in the diaphysis, a 
secondary ossification center in the epiphysis and a growth plate between diaphysis and 
epiphysis that regulates the longitudinal growth. The growth plate is divided in a 
chondrocytes-rich reserve zone, a proliferative zone, pre-hypertrophic zone and 
hypertrophic zone (Fig. 5) (Aszódi et al., 2000). 
 
Figure 5: Endochondral ossification, growth plate composition and molecules synthesized 
in different bone developmental stages. (Behonick et al., 2003) 
 
The different phases of intramembranous and endochondral ossification are characterized 
by typical changes in matrix composition. Cartilage cells, chondroblasts and 
chondrocytes, synthesize collagen fibrils of Collagen type II, type IX and type XI. The 
differentiation of chondrocyte cells is marked by different collagen elements and 
hypertrophic chondrocytes produce Collagen X that is involved in matrix mineralization. 
Early differentiated osteoblasts are characterized by the expression of Runt domain-
containing transcription factor (Runx2), while at the end of differentiation these cells 
produce also Osterix (Osx or sp7), which is regulated by Runx2. Fully differentiate 
osteoblasts express Osteocalcin (OCN or BGLAP) and Bone sialoprotein (BSP) (Harada 
& Rodan, 2003). 
 
 
1.11 FGF signaling 
 
Fibroblast growth factor (FGF) signaling is a crucial pathway required during 
development, but also to maintain cell homeostasis in adult organs. It is involved in 
multiple processes such as proliferation, differentiation, cell migration, angiogenesis, 
morphogenesis and regulation of metabolism. 
The FGF family in humans is formed by 18 FGF ligands and 4 FGF receptors (FGFr). 
FGF receptors are composed by a single peptide chain which carries a glycosylated 
extracellular ligand binding domain, a transmembrane domain and a cytoplasmic portion 
with tyrosine kinase activity. The extracellular chain has IgG-like domains that 
selectively bind heparan sulfate and FGFs, giving to each receptors the ability to link a 
unique subset of ligands. 
FGF ligands have a conserved hydrophobic patch that interacts with FGF receptors 
(FGFr) and a unique heparan sulfate binding surface that differs among FGFs and gives 
their binding specificity (Mckeehan et al., 2009). Heparan sulfate specific interaction with 
FGF ligands permits to control the location and the trafficking of FGFs, provides the 
specificity of FGFs/receptors binding and regulates ligands lifetime and stability by 
protecting FGFs against proteinases. Extracellular matrix and tissue architecture have an 
important role in the regulation of FGF signaling activation (Mckeehan et al., 2009).  
Crystallographic analysis has shown that the ternary complex, composed by FGFr-FGF-
HS, recruits a second ternary complex forming a dimer with the stoichiometry of 2 FGFr-
2 FGF- 2 HS. The dimerization is necessary for the transphosphorylation and activation 
of intracellular receptor kinases and the downstream pathways. 
FGF signaling is associated with different downstream pathways, including 
RAS/mitogen-activating protein (MAP) kinase pathway, phosphoinositide 3 (PI3) 
kinase/AKT pathway and phospholipas A). After the 
binding of FGF ligands to the receptor, there is a phosphorylation of tyrosine residues in 
the FGFr cytosplasmic domain and the consequent interaction of adaptor proteins 
associated with the signaling, that form a complex required for the activation of 
RAS/MAP kinase and PI3 kinase/AKT pathways. RAS/MAP kinase is implicated in cell 
differentiation and proliferation, while PI3 kinase/AKT pathway is associated with 
it controls cell morphology, adhesion and migration (Teven et al., 2014) (Fig. 6 A). 
The negative regulation of the signaling occurs with the internalization and degradation 
of the FGF receptor or with the activation of MAPK phosphatases. The phosphatases 
Sprouty, Sef and Dusp6 are directly regulated by FGF signaling through a feedback 
autoinhibitory way and they block MAP kinase pathway activity. Sprouty and Sef 
proteins suppress RAS/MAP signaling at multiple levels within the pathway, while 
Dusp6 acts only by dephosphorylating ERK (Teven et al., 2014) (Fig. 6 B). All these 
regulators have an important control role in the spatio-temporal expression, intensity and 
duration of FGF signaling, that are essential factors in normal development and diseases.  
 
 
Figure 6: (A) FGF signaling downstream pathways, image modified from (Teven et al., 
2014) (B) Schematic FGF/RAS/MAPK pathway showing Sproutys, Sef and Dusp6 
blocking roles. Image modified from (Molina et al., 2009). 
 
FGF signaling controls many embryonic and postnatal stages of skeletal development. 
(Fig. 7) and 
mutations altering the FGF  pathway activity cause different bone pathologies, such as 
chondrodysplasia and craniosynostosis (Ornitz et al., 2002). FGF ligands and receptors 
expression are strictly spatially and temporally regulated in bone and cartilage 
development. It has been shown that low FGF signaling activity is associated with 
proliferation, while enhanced pathway leads to cell differentiation and apoptosis (Ornitz 
et al., 2002). Then, by interacting with other cellular pathways, FGF signaling controls 
each step of the chondrogenic and osteogenic pathways. Moreover, it orchestrates the 
A B 
balance among cell growth, differentiation and apoptosis, leading to the correct bone and 
cartilage morphogenesis (Ornitz et al., 2002). 
FGF signaling has been found to activate the expression of important bone transcription 
factors, such as Runx2 and Osterix and bone matrix-related genes, such as Collagen1 
(Felberet et al., 2015). 
 
Figure 7: Regulatory pathways in endochondrial (A) and intramembranous (B) 
ossification. FGF signaling is involved in many stages: reserve (R), proliferating (P), 
prehypertrophic (PH) and hypertrophic (H) stages in chondrocytes progress; proliferation, 
differentiation, osteogenesis and apoptosis stages of osteoblasts maturation. Other 
signaling pathways are involved and interact with FGF signaling: Indian hedgehog (IHH), 
patched (PTC), smoothened (SMO), bone morphogenic proteins (BMPs), parathyroid 
hormone related peptide (PTHrP) and PTHrP receptor (PPR). Image modified from 
(Ornitz et al., 2002). 
 
 
1.12 Zebrafish as animal model 
 
Mouse models are the most frequently used biological tools for the study of human 
disorders, because they offer  many advantages over other animal models, such as a high 
degree of protein sequence homology to human proteins and anatomical and 
physiological similarity with humans. However, given the complexity of generating 
mouse models for target diseases and for their performing molecular analysis, alternative  
animal models  have been exploited by researchers in the past decades. 
A recently largely used organism for the analysis of human diseases is the vertebrate 
Danio rerio , 
A 
B 
which has been used from the 1930s as a vertebrate model for studies of developmental 
biology and  embryogenesis.  
In the last years, zebrafish has been also used for the analysis of pathogenic mechanisms 
of many human diseases and studies of drugs efficacy.  
This organism has a small size: its length reaches 4cm in adults and 2mm in embryos, so 
to 300 eggs in a week, enabling to perform large-scale studies in a short time.  
Unlike mouse, zebrafish fertilization and embryonic development occurs externally, 
follow organ development using an optical microscope since zebrafish embryos are 
optically transparent. By adding phenylthiourea (PTU) to the fish water the pigmentation 
can be blocked and zebrafish are kept transparent also at late life stages.  
Bioinformatics studies have detected a great similarity between the Danio rerio genome 
and the human one with a significant synteny among conserved genes. Zebrafish genome 
has been almost entirely sequenced and recent analysis have demonstrated that zebrafish 
has a diploid genome, with many genes that underwent duplication events during 
evolution (Lieschke et al., 2007). 
The development of several techniques of forward and reverse genetics has amplified the 
possibility of using zebrafish as animal model. In the past decades forward genetic 
techniques, such as insertional retroviral mutagenesis and chemical mutagenesis with the 
use of N-ethyl-N-nitrosourea (ENU), have allowed to collect thousands of zebrafish 
mutants.   
Among the different reverse genetic techniques a widely applied technology is the 
microinjection of antisense morpholinos, that induce a temporal block of gene 
transduction or interfere with transcript splicing, and the site-directed mutagenesis 
(Lieschke et al., 2007).  
Transgenic zebrafish line expressing fluorescent proteins under the control of tissue-
specific promoters or signaling-specific promoter elements, have permitted to follow in 
vivo the development of tissues and organs and to identify key signaling pathways 
involved in physiological processes (Hammond & Moro, 2012). 
 
 
1.13 Zebrafish as model for bone diseases  
 
Zebrafish has been also recently used as model to study bone development and 
ossification defects. 
It shares similar developmental mechanisms in skeletal morphogenesis and bone cell 
types with higher vertebrates. However, fish bones are located in simple spatial patterns 
and they are composed of a small number of cells. Zebrafish bone mineralization starts 
already at 3dpf in the cephalic regions and when compared to higher vertebrates, 
craniofacial bones develop in a similar way (Fig. 8). Many of the molecular mechanisms 
controlling early stages of bone development are evolutionary conserved, including gene 
regulatory networks that regulate osteogenesis (Mackay et al., 2013). The zebrafish 
craniofacial skeleton contains bones that have both dermal and chondral origins, which 
arise from neural crest or mesodermal progenitor cells. 
The external fertilization and the optical transparency, permit to completely follow the 
development of osteogenic and chondrogenic specific cells. Furthermore, by using 
fluorescent transgenic reporter lines marking 
image in real time bone formation. It is also possible to track in vivo bone matrix 
formation using particular dyes that bind to mineralized tissue, such as Alizarin red or 
calcein (Hammond & Moro, 2012). 
Zebrafish can be used to study  pathogenic mechanisms of bone-related disorders arising 
from very early stages of  bone and cartilage development. To perform this task, more 
recently, different biosensor transgenic reporter fish for the main cell signaling pathways 
have been generated (Hammond & Moro, 2012). 
A large-scale forward genetic screening has permitted to identify new gene functions 
important for bone formation and several mutant zebrafish lines have been characterized 
and correlated with human bone pathologies, such as osteogenesis imperfecta and 
craniosynostosis (Mackay et al., 2013). 
Zebrafish have been studied also as model for lysosomal storage disorders with the 
generation of a mutant for Mucolipidosis II (Flanagan-Steet et al., 2009). 
 
 
Figure 8: Schematic picture showing the structural of skeletal elements of zebrafish, 
mouse and human. D1: palatoquadrate (zebrafish) - incus (mouse and human); V1: 
- stapes (mouse and human); V2: 
ceratohyal (zebrafish) - 
(zebrafish) - styloid bone (mouse and human). Modified from Schilling et al.,1997 
(Schilling et al., 1997). 
1.14 Animal models for Mucopolysaccharidosis type II 
 
Spontaneous canine and feline animal models have been used to study new therapeutic 
strategies for mucopolysaccharidosis type II. However, the size and the lifespan of these 
models hamper the characterization of the disease. For this reason, a mouse model for 
Hunter syndrome has been generated few years ago (Garcia et al., 2007), harboring a 
large deletion of exon 4 and part of exon 5 in the iduronate 2-sulfatase gene, leading to 
the synthesis of a non-functional IDS enzyme.  
IDS-KO mice have no pathological manifestations at birth, but develop typical MPSII 
manifestations over time, such as GAGs accumulation in tissues from 7 weeks (Fig. 9 A-
B), increased organs size and elevated urine GAGs excretion from 4 weeks (Garcia et al., 
2007). 
The first macroscopically evident manifestations are visible by 8 months of age, when all 
mutant mice show broadened snout and abnormal skull development. 
Radiological analysis in IDS-KO mice display sclerosis and enlargement of the skull 
bones from 4 weeks of age and appendicular bone enlargement from 10-13 weeks. The 
severity of skeletal defects is progressive and mutant mice show skull enlargement (Fig. 9 
C), thickened long bones in the hind limbs, ribs and vertebrae, and an overall increased 
bone density (Fig. 9 D-E) compared with age-matched WT mice (Garcia et al., 2007). 
 
 
Figure 9: (A-B) Representative examples of Alcian blue staining and GAG accumulation 
in liver sample from 20 weeks old wild-type (A) and IDS-KO (B) mice. (C-E) 
Radiographs of an IdS-KO (age 57 weeks) and a wild-type mice (age 53 weeks) showing 
the head (C), hind limbs (B) and torso (C). IDS-KO mice display thickened bones of the 
skull, ribs and hind limb and the overall increased radio-opacity (bone density). Scale 
(white bar)=1 cm. Z, zygomatic bone; N, nasal bone; T, tibia; F, femur; C, calcaneus 
bone. Images modified from (Garcia et al., 2007). 
 
An alternative vertebrate model for MPSII has been generated by using the morpholino 
technology in zebrafish. The reduced Ids activity detected in zebrafish morphants is 
associated with early development defects, such as altered migration and differentiation 
of neural crest cells into chondroblasts (Moro et al.,2010). Moreover zebrafish morphants 
display impaired development and altered facial cartilage morphogenesis (Fig. 10). These 
that in turn upregulates mesodermal genes expression (Moro et al., 2010). 
 
 
Figure 10: (A) Representative images of a WT embryo (top) and an Ids morphant 
(bottom) at 5dpf. (B) Abnormal head cartilage morphogenesis in Ids morphant (on the 
bh:basihyal, 1-2-3-4-5:branchial arches. Images modified from (Moro et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 METHODS 
 
 
2.1 ZEBRAFISH 
 
2.1.1 Zebrafish husbandry 
 
All procedures involving fish husbandry and manipulation were evaluated and accepted 
by the Local Ethical Committee of the University of Padova.  
All mating procedures were carried out at the Fish Facility  in the Department of Biology 
of the University of Padova. 
Larvae were kept for the first five days in Petri dishes, then maintained at 28°C for the 
following stages in 5 liters tanks filled with fish water at neutral pH.  
 
2.1.2 Injection 
 
For the microinjection experiments, the DNA constructs of interest were resuspended in 
Danieau buffer (8 mM NaCl, 0,7 mM KCl, 0,4 mM MgSO4, 0,6 mM Ca(NO3), 2,5 mM 
HEPES, pH 7.6) and Red Phenol (Sigma, Milan, Italy) at the working concentration. All 
solutions were injected into one cell-stage embryos, using a light microscope and a 
microinjection apparatus.  
 
2.1.3 Oligo Morpholino 
 
Morpholino is a synthetic oligo of 25bp, designed to target a specific mRNA. This oligo 
recognizes and binds the target sequence, blocking mRNA translation or interfering with 
mRNA maturation by a direct binding to a specific splicing site.  
Two different types of oligo morpholino were used: 
-Translation blocking: The oligo is synthesized to bind a region near the ATG codon, 
sterically blocking the translation initiation complex and therefore knocking down protein 
expression. The ATG morpholino can block the translation of both maternal and zygotic 
transcripts. 
-Splicing site blocking: The morpholino recognizes a splicing site on the pre-mRNA, 
modifying the normal splicing event. This oligo can target zygotic transcripts processing.  
These synthetic oligos are modified when compared to normal nucleic acid sequences. 
They carry morpholino rings instead of deoxyribose sugar moieties and non-ionic 
phosphorodiamidate linkages replacing the anionic phosphates. Their modified structure 
enables them to be nuclease-resistant and stable inside the cells. Moreover, they have 
been shown non-immunogenic and able to trigger enzymatic or signaling proteins 
response. Although the high resistance, each designed morpholino remains stable and 
active only for five to six days into cells before being degraded. 
I have designed and used  two different morpholinos: one against the ATG sequence (Ids 
start morpholino) and the other targeting a splicing donor site (Ids splicing morpholino) 
(Table 2 and 3). All experimental results obtained in morphants were compared with 
those from fish injected with control mismatch morpholinos, carrying a mismatched 
sequence and unable to recognize the target mRNAs (Ids splicing morpholino CONTROL 
and Ids start morpholino CONTROL) (Table 2). 
 
 
 
 
 
Table 2: Sequences of the different morpholino used in the experimental procedures.  
 
All morpholinos were purchased from Genetools (Philomath, OR, USA) and the stock 
solutions were resuspended in DNase/RNase free water in a final concentration of 
300nM. 
Several injection experiments have been performed in 
concentration.  
For Ids translation blocking morpholino, 3 different concentrations have been tested: 
 
1,2 , in agreement with a previous experimental set-up 
(Moro et al., 2010). To confirm the efficacy of the tested morpholino, Western blot 
analysis were performed using protein extracts from morphants and control larvae  
The Ids splicing-blocking morpholino is designed to a target exon2 - intron2 donor splice 
site (Table 3). Five different concentrations were tested
 RT-PCR I amplified the region surrounding the splicing donor site 
(Table 4). Gel electrophoresis of the amplified region showed that in morphants there was 
a decrease in the intensity of the expected amplicon, and the appearance of lower weight 
bands, when compared to mismatch control sample (Fig. 11 and 12). Sequencing analysis 
of the fragment with highest molecular weight (Fig. 12 arrow) showed that the 
morpholino produced a deletion of 22bp between exon2 and exon3 (Fig. 13), creating a 
premature stop codon and the formation of a truncated 172 aminoacids protein (Fig. 14). 
According to the sequencing profile of the low weight bands, I could conclude that the 
Ids splicing morpholino caused an alternative splicing, and triggered a nonsense-mediated 
Oligo name Antisense sequence 
Ids splicing morpholino AATTATGCACGCGTCATACCAGGAT 
Ids splicing morpholino CONTROL AATAATCCACCCGTCATACGACGAT 
Ids start morpholino GTAAATACGAGCATTACATTCATTG 
Ids start morpholino CONTROL GTTAATACCAGGATTAGATTGATTG 
decay of the transcripts. Best results have been obtai
concentration and, therefore, all experimental procedures involving the splicing 
morpholino were done at the chosen optimal concentration.  
 
 
GGAATTCTCTAAACAGCATAAAACAAACATGTGAAAGAAGTATCTGAA
ACGAAACCGCGCAACACA 
Exon 1 
ATGAATGTAATGTTCGTATTTACGTGTTGGTGGTTTGTTTTTATTTTTC
ACCTTTTGGGGCGAGATGTTTTTGCAGCAAAAAGCAAAGATTTCAACGT
TTTGTATTTAATTGCTGACGATCTGAGACCATCTTTAGGCTGTTATTCTG
ATCCAGTGGTCAAATCACCGAACATCGATCAGCTTGCATCTTTGAGCGT
AGTGTTTCATAACGCATATGCCCAG 
Intron 1 
GTATGTTGTATTAATGCTCATGGAA..........TATATTACAATGTGTTCTTTC
AAAG 
Exon2 
CAAGCTGTTTGTGGACCTAGTAGAGTGTCTTTCCTAACAAGTCGAAGAC
CAGACACCACAAAACTCTACGATTTCAACTCATACTGGAGAGTTCATGC
TGGAAACTACACCACACTACCTCAATACTTCAAGTCTAATGGATACACC
ACTTTATCAGTGGGCAAAGTCTTCCATCCTG 
Intron2 
GTATGACGCGTGCATAATTTTCACG..........TCTCTTTCACGTGCTTGTCC
TCAAG 
Exon3 
GCATTGCCTCCAACCACTCGGATGATTACCCGTACAGCTGGTCTGTACC
GCCGTATCATCCACCCTCTTTTGAATATGAAAAGAGGAAG 
Table 3: Iduronate 2-sulfatase sequence of Exon 1-2-3 and Intron 1-2. In green the 
sequence targeted by the IDS start morpholino. In red the sequence targeted by the Ids 
splicing morpholino and in blue the splicing donor site. RefSeq NM_001080068 
 
 
Figure 11: Gel electrophoresis showing the amplicons produced by Ids splicing 
bands in morphant extracts and the single band in the control sample. 
 
 
Figure 12: Gelelectrophoresis showing the amplicon produced by Ids splicing morpholino 
the same sample. Note the lower amount of ids transcripts when compared with the 
control sample. The arrow shows the sequenced fragment. 
 
 
 Primer RefSeq 
External ids For TCGTATTTACGTGTTGGTGGT NM_001080068 
External ids Rev CCCTTCATAGAGCGCAAGAG NM_001080068 
Inner ids For GCTTGCATCTTTGAGCGTAGT NM_001080068 
Inner ids Rev CCCTTCATAGAGCGCAAGAG NM_001080068 
GAPDH For GTGGAGTCTACTGGTGTCTTC NM_001115114 
GAPDH  Rev GTGCAGGAGGCATTGCTTACA NM_001115114 
Table 4  
 
ATGAATGTAATGTTCGTATTTACGTGTTGGTGGTTTGTTTTTATTTTTCAC
CTTTTGGGGCGAGATGTTTTTGCAGCAAAAAGCAAAGATTTCAACGTTTT
GTATTTAATTGCTGACGATCTGAGACCATCTTTAGGCTGTTATTCTGATC
CAGTGGTCAAATCACCGAACATCGATCAGCTTGCATCTTTGAGCGTAGTG
TTTCATAACGCATATGCCCAGCAAGCTGTTTGTGGACCTAGTAGAGTGTC
TTTCCTAACAAGTCGAAGACCAGACACCACAAAACTCTACGATTTCAAC
TCATACTGGAGAGTTCATGCTGGAAACTACACCACACTACCTCAATACTT
CAAGTCTAATGGATACACCACTTTATCAGTGGGCAAAGTCTTCCATCCTG
GCATTGCCTCCAACCACTCGGATGATTACCCGTACAGCTGGTCTGTACCG
CCGTATCATCCACCCTCTTTTGAATATGAAAAGAGGAAGGTTTGCAAAG
ATAAAGACGGCACGTTGCACAGTAACCTGCTGTGTCCCGTGAACGTGTC
TGAAATGCCTCTAGGAACCCTTCCTGACATGGAGAACACAGAGGAGGCC
ATTCGACTCTTGCGCTCTATGAAGGGCTCACAAAAACCATTCTTCCTGGC
TGTCGGCTTCTATAAACCTCATATTCCTTTCAGAATCCCACAG        
Figure 13: Iduronate 2-sulfatase cDNA sequence of exon 1-2-3-4. In yellow the 22bp 
deletion produced by Ids splicing morpholino.  
 
 
Figure 14: Prediction of Ids aminoacid sequence with the 22bp deletion in the transcripts. 
In yellow the first aminoacid alteration and in red the premature stop codon. 
 
 
2.1.4 Protein extraction 
 
Proteins were extracted from 50 morphant and control larvae at 2dpf. Before the lysis, 
fish yolk was removed using a Deyolking buffer (55mM NaCl, 1,8mM KCl, 1,25mM 
NaHCO3) and the samples were washed with Washing buffer (110mM NaCl, 3,5mM 
Exon 1 
Exon 2 
Exon 3 
Exon 4 
KCl, 2,7mMCaCl2, 10mM Tris-HCl pH 8.5). Tissue lysis was performed by using a 
Tissue extraction lysis buffer II (Invitrogen) added with protease and phosphatase 
inhibitors. Samples were homogenized with a sonicator and proteins were isolated from 
other cellular components by centrifugation. 
Protein extracts were quantified under spectrophotometric analysis using Pierce BCA 
Protein Assay kit (Thermo Fisher Scientific). 
 
2.1.5 Western blot 
  
This technique permits to evaluate amount of a protein of interest in a protein lysate using  
a specific antibody. In this work western blot analysis have been performed to evaluate 
the degree of Ids knockdown in protein extracts of morphant fish and control samples. 
racts have been separated on Nu-PAGE® Novex® 4 12% 
Bis-Tris Gels (Invitrogen) after a denaturation and transferred to PVDF membranes. The 
membranes were subsequently incubated with antibodies against iduronate 2-sulfatase 
(1:1000; Novus biologicals) and -actin (1:5000; Santa Cruz) at 4°C overnight after 
blocking with Western blocker solution (Sigma) for 2h. -actin was used as an 
endogenous control for protein quantification, while a HeLa cells sample was used to 
verify the specificity of the used antibody. 
After the incubation with horseradish peroxidase conjugated secondary antibody (1:2000; 
Sigma) for 1 h at room temperature, visualization was performed with SuperSignal West 
Pico Chemiluminescent Substrate detection kit (Thermo Scientific) followed by exposure 
to X-ray film (Thermo Scientific).  
Ids quantification was performed by band specific densitometric analysis (ImageJ) and 
normalizing the value obtained with that of -actin specific bands. 
 
2.1.6 Synthesis of RNA antisense probe 
 
RNA labeled probes have been used for in situ hybridization analysis to recognize 
transcripts of interest. Plasmids containing the partial coding sequence of a target gene, 
flanked by phagic RNA polymerase transcription initiation sequences were used to 
synthesize antisense riboprobes. To generate the antisense riboprobes  plasmids have 
been linearized upstream of the target cDNA coding sequences, while the probes have 
been transcribed using a downstream promoter (Table 5). The transcription process was 
carried out in the presence of digoxigenin-labeled nucleotides allowing the generation of 
a labeled antisense riboprobe, using mMessage mMachine SP6, T7 or T3 Kit (Ambion). 
 
Probe Plasmid Enzyme for linearization Promoter 
mcherry pME ApaI T7 
GFP pME ApaI T7 
fgfr3 pBSII SK KpnI SP6 
fgf3 pBSII SK SalI T3 
fgf8 pBSII SK XhoI T7 
pea3 pSPORT6.1 KpnI T7 
ntl pBSII SK KpnI T7 
spry4 BluScript SalI SP6 
Table 5: RNA antisense probe synthesized with information about plasmid, enzyme used 
for linearization and promoter used for their synthesis.  
 
2.1.7 In situ hybridization (ISH) 
 
This technique allows to detect transcripts of a gene of interest using a labeled antisense  
riboprobe complementary to the target sequence. In  whole mounted larvae after ISH
possible to identify the spatial distribution of target transcripts in different anatomical 
regions. 
I performed in situ hybridization in larvae of different developmental stages using the 
probes for: 
- Runx2b, a marker expressed in the early stages of ossification. 
- ColX(col10a1), a marker of hypertrophic chondrocytes.  
- mCherry and GFP for the detection of the reporter protein in transgenic.  
- fgfr3, one of FGF signaling receptors. 
- fgf3 e fgf8, two FGF signaling ligands. 
- pea3, ntl e spry4, FGF signaling target genes. 
The hybridization temperature was different according to the probe length and the 
percentage of G-C content (Table 6). 
The probes were digoxigenin-labeled, therefore recognized by an alkaline phosphatase-
conjugated antibody against-digoxigenin. The alkaline phosphatase substrate NBT/BCIP 
was used to perform the colorimetric detection of the in situ hybridization. 
After ISH, larvae are mounted in 85% glycerol and photos have been acquired using a 
Leica S8AP0 microscope.  
 
 
 
 
 
 
 
Probe Temperature of hybridization 
Runx2b 62°C 
ColX 62°C 
mcherry 62°C 
GFP 62°C 
fgfr3 64°C 
fgf3 62°C 
fgf8 62°C 
pea3 64°C 
ntl 64°C 
spry4 64°C 
Table 6: RNA antisense probes used and their temperature of hybridization 
 
2.1.8 Crispr/Cas9 
 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 is a new 
gene editing tool used to efficiently achieve target gene modifications in different animal 
models, including zebrafish. This system is naturally present in Eubacteria and Archea as 
an adaptive immune response against exogenous genetic elements such as plasmids and 
phages.  
in vitro through the synthesis of a guide RNA 
(gRNA) and the mRNA encoding Cas9 endonuclease. The gRNA is an RNA sequence, 
formed by the fusion of a CRISPR-RNA(crRNA) and a transactivating RNA (tracRN), 
that guides the Cas9 enzyme to the target sequence. The crRNA is complementary to the 
sequence of interest in the genome, while the tracRNA is an RNA element recognized by 
the Cas9 enzyme. The genome target is generally 20bp long and upstream of a PAM 
(Protospacer Adjacent Motif
target sequence at the PAM motif producing a double strand break and by NHEJ (Non-
homologous end joining) repairing, unpredictable gene mutations such as insertions and 
deletions can be produced at the target locus.  
To create a zebrafish mutant, a predesigned gRNA and the mRNA encoding for Cas9 
have been injected in one-cell stage embryos. The synthesis of the gRNA was performed 
with T7 Megashortscript kit (Ambion), the mRNA of Cas9 was synthesized with 
mMessage mMachine SP6 kit (Ambion). Injected fish (F0) are generally mosaics 
carrying several mutations in different cell lineages. Only germline  mutations can be 
transmitted to the offspring. The F0 fish are then crossed with wild type fish, to produce 
the F1 carrying a single inheritable mutation. Homozygous mutant fish can be obtained 
only in the second generation progeny (F2) by incross of two heterozygous carriers. To 
produce an iduronate 2-sulfatase fish mutant, I followed the protocol illustrated by Jao 
and colleagues (Jao et al., 2013). 
PCS2-cas9 and pT7cas9sgRNA2 plasmids were purchased from Addgene.  
The plasmid PCS2-cas9 contains a Cas9 cDNA, flanked by SV40 large T-antigen nuclear 
localization signals (nls) at the N-terminus  and C-terminus. 
The pT7cas9sgRNA2 plasmid carries the crRNA:trascRNA backbone downstream to a 
region in which it is possible to clone the sequence complementary to the target gene 
region. 
The target sequence needs 
efficient T7-mediated transcription from the promoter, and a PAM motif, for efficient 
Cas9 binding (Jao et al., 2013). 
A target sequence in the first and second exon of the ids was chosen and cloned in the 
pT7cas9sgRNA2 plasmid.  
Two different software have been used to define the sequence of interest:  
E-CRISP  (http://www.e-crisp.org/E-CRISP/)  
CHOPCHOP (https://chopchop.rc.fas.harvard.edu/) (Fig. 15) 
A target sequence in the first part of the ids exon 2 
(GTTAGGAAAGACACTCTACTAGG) was identified by in silico analysis. To create a 
double-stranded oligo to be cloned in the gRNA plasmid, I produced two single-stranded 
oligos according to previous published guidelines (Jao et al.,2013). The sequences of the 
-TAGGTAGGAAAGACACTCTACT-  and -
ATCCTTTCTGTGAGATGACAAA- .  
A Cas9 mRNA and the gRNA have been transcribed and co-injected in one cell-stage 
embryos at different concentrations to evaluate both the toxicity and the efficacy. Injected 
fish have been analyzed for mortality and phenotypic abnormalities, allowing to define 
  Injected fish at 
2dpf were sacrificed and genotypized to identify the indels.   
 
 
Figure 15: CHOPCHOP results for target sequences in iduronate 2-sulfatase exon 2. The 
red arrow show the chosen target sequence. 
 
 
 
 
2.1.9 DNA extraction 
 
DNA was extracted from whole larvae or adult tail samples. Tissues were digested with 
SDS-containing lysis buffer (Tris/HCl 1M, NaCl 1M, EDTA 0,5M, SDS 20%) and a 
10mg/ml proteinase K solution  at 55°C overnight.  Total genomic DNA was 
purified by phenol chloroform extraction and ethanol precipitation. Purified DNA was 
dissolved in DNase-free water and quantified with NanoDrop instrument (Agilent). 
 
2.1.10 High resolution melting (HRM) 
 
High resolution melting (HRM) is a rapid method for the detection of mutations or 
polymorphisms in double stranded DNA samples. This technique relies on the different 
melting temperatures of the WT or mutated DNA amplicons. This method was used to 
screen for candidate fish mutants in the F0 generation.  
In the presence of a fluorescent dye (LCGreen PlusTM) linking the double strand DNA 
amplicons are denaturated and then renaturated to produce heteroduplex.  
To screen for F0 fish, a large sequence around the target region encompassing all possible 
mutant alleles was scrutinized (Table 7).  
Once identified the type of induced mutation a second pairs of oligos was used to perform 
genotyping and detect homozygous mutant fish. 
 
 Primer  RefSeq 
Primer to screen F0 fish For GATCAGCTTGCATCTTTGAGC NM_001080068 
Primer to screen F0 fish Rev TTGTGGTGTCTGGTCTTCGA NM_001080068 
Primer to screen Ids-KO fish For TGTGTTCTTTCAAAGCAAGCTG NM_001080068 
Primer to screen Ids-KO fish Rev TTGTGGTGTCTGGTCTTCGA NM_001080068 
Table 7: Primer used to amplify the target ids region for HRM analysis. 
 
2.1.11 Characterization of the mutant allele by cloning 
 
To better define the mutant allele, the amplicon containing the targeted sequence was 
purified, and ligated to a TOPO vector ( ). Transformed competent cells were 
plated on agar containing the selective antibiotic. Single grown colonies were picked and 
cultured in Luria Bertani medium. The extraction and purification of plasmid DNA was 
performed using commercial kits provided by Qiagen (QIAprep®). 
Plasmids from different colonies were sequenced and analyzed (Fig. 16). 
 
 
 
2.1.12 Homozygous mutant fish screening using PCR analysis  
 
To identify homozygous mutant fish, a complementary PCR-technique was used. This 
approach was based upon the design of a reverse oligo containing a stretch of nucleotides 
reverse oligo fails to anneal, thus preventing the generation of an amplicon as shown in 
Fig. 17 (Table 8). 
 
 
Figure 17: Gel electrophoresis of the amplicons obtained from homozygous mutant and 
WT sibling DNA. CN: negative control, CP: positive control (WT sequence), Ho: 
homozygous Ids mutant.  
 
 Primer  RefSeq 
Primer that amplify on 
the deletion For GCTTGCATCTTTGAGCGTAGT NM_001080068 
Primer that amplify on 
the deletion Rev GACTTGTTAGGAAAGACACTCTA NM_001080068 
Primer that amplify 
around the deletion For GCTTGCATCTTTGAGCGTAGT NM_001080068 
Primer that amplify 
around the deletion Rev ACGTCTATTTAGTCAGTGGGTTT NM_001080068 
Table 8: List of primer used to screen homozygous fish 
 
2.1.13 Enzymatic assay 
 
This assay was used to quantify Ids enzymatic activity in 2dpf larva and isolated organs 
(brain, liver and muscle) of 2 months old Ids-KO and WT fish. Samples were obtained by 
Figure 16: Comparison between 
four different colonies after 
sequencing. Colonies 3 and 4 
display a deletion of 5bp 
compared to colonies 1 and 2. 
homogenizing larvae or tissues in ice with a lysis buffer (Invitrogen). Debris was pelleted 
twice by centrifugation at 4°C and supernatants were collected and assayed for total 
protein concentration (mg/ml) by the Bio-rad protein assay (Biorad). 
Iduronate 2-sulfatase activity was determined by a 2-step fluorimetric assay using the 
substrate 4-methylumbelliferyl- -iduronate 2-sulfate (MU- ldu-2S). Results were 
obtained using 4-methylumbelliferone as a standard and were normalized to total protein 
levels. Ids activity was expressed as 1 nmol of MU- -2S substrate hydrolysed in 4 h 
per mg total proteins (nmol/4h/mg). 
 
2.1.14  Paraffin-embedding and sectioning 
 
Zebrafish were fixed in 4% PFA in PBS, washed in PBS and dehydrated in ethanol 
solutions of increasing concentrations. Zebrafish samples were dehydrated with butanol. 
All solutions were removed and substituted with paraffin. Sectioning was performed 
using a microtome and tissue sections were collected on Superfrost slides. 
 
2.1.15 Immunohystochemistry 
 
Immunohystochemical analysis was carried out on whole mount zebrafish. For whole 
mount immunohystochemistry a previously published protocol was considered (Inoue & 
Wittbrodt, 2011). Zebrafish were fixed in 4% PFA in PBS and stored in 30% sucrose. 
Primary antibody (Iduronate 2 sulfatase 1:100, Novus) (GFP 1:100, Thermo Fisher) was 
incubated 3 days at 4°C, while the secondary antibody (Goat anti-Mouse IgG Fc TRITC 
conjugate 1:200, Thermo Fisher) (Goat anti-Rabbit IgG (H+L) FITC conjugate 1:200, 
Thermo Fisher) was incubated 2 days at 4°C in the dark.  
 
2.1.16 Transgenic reporter lines 
 
I have used different transgenic zebrafish reporter lines: 
-Lipan Tg(lfabf:dsRed; elaA:EGFP) expressing the fluorescent protein dsRed under the 
control of a liver-specific promoter and the fluorescent protein GFP under the control of a 
pancreas-specific promoter. This line was used to analyze liver size in fish morphants and 
mutants (Korzh et al., 2008). 
-Tg(sox10:mRFP)vu234 express the fluorescent protein RFP under the control of a Sox10 
promoter. Sox10 is a marker of neural crest precursors that may differentiate into 
chondroblasts (Kirby et al., 2006). 
-Tg(Col2a1aBAC:mCherry)hu5900 express the fluorescent protein mCherry under the 
control of a Collagen 2-specific promoter (Hammond & Schulte-merker, 2009). 
-Tg(Ola.Sp7:NLS-GFP)zf132 express the fluorescent protein GFP under the control of a 
Osterix specific- promoter (Spoorendonk et al., 2008). 
-TgBAC(col10a1:Citrine)hu7050 express the fluorescent protein Citrine under the control of 
a Collagen X-specific promoter (Mitchell et al., 2013). 
To evaluate which signaling pathways may be  involved in MPSII pathogenesis newly 
generated transgenic lines have been used: 
-Tg(BMPRE:EGFP)ia18 and Tg(BMPRE:nlsmCherry)ia17  transgenic reporter lines for the 
BMP signaling pathway (Moro et al., 2013). 
-Tg(12xSBE:EGFP)ia16 and  Tg(12xSBE:nlsmCherry)ia15 transgenic reporter lines for the 
 signaling pathway (Casari et al., 2014). 
-Tg(12xGli-Hsv.TK:GFP)ia11and Tg(12xGli-Hsv.Ul23:nlsmCherry)ia10 transgenic reporter 
lines for the Shh signaling pathway (Corallo et al., 2013). 
-Tg(7xTCF-Xla.Siam:GFP)ia4 and Tg(7xTCF-Xla.Siam:nlsmCherry)ia5 transgenic reporter 
lines for the canonical Wnt signaling pathway (Moro et al., 2012). 
-Tg(EPV.Tp1-Mmu.Hbb:nlsmCherry)ia7 transgenic reporter line for the Notch signaling 
pathway (Moro et al., 2013). 
-Tg(Dusp6:d2EGFP)pt6 transgenic reporter line for the FGF signaling pathway. This line 
express the fluorescent d2GFP destabilized protein under the control of a Dusp6 
promoter, whose expression is regulated by the FGF signaling (Molina et al., 2007). 
 
2.1.17 Image acquisition 
 
Fluorescence was visualized and acquired using the conventional fluorescence dissecting  
microscope Leica M165FC and the confocal microscope Nikon C2 H600L. For 
brightfield and fluorescence imaging with the dissecting microscope, embryos  and  
larvae  were  anesthetized  with  tricaine  and  mounted  in  2% methylcellulose.  For  
confocal  imaging,  anesthetized  embryos  and  larvae were embedded in 1% low melting 
agarose. The fluorescence was visualized using 488 nm (for GFP, d2GFP and Citrine) 
and 561 nm (for mCherry and dsRED) lasers and 20x or 40x immersion objectives 
(Nikon). 
 
2.1.18 Image analysis 
 
Images were analyzed using ImageJ program or Imaris software, on confocal Z-stack 
projections or conventional fluorescence microscope acquisitions. 
Statistical analyses were carried out with Prism software (GraphPad). 
 
2.1.19 Alcian blue in whole mount fish 
 
This technique was used to analyze the cartilage in 5dpf fish. Larvae were fixed overnight 
in 4% PFA in PBS at 4 °C, washed in PBS and stained overnight at room temperature in 
Alcian blue solution (70% EtOH, 1% HCl, 0.1% Alcian blue). Larvae  were  then  cleared  
in  3%  hydrogen  peroxide  and  1%  KOH,  rinsed  in  70%  EtOH  and  whole  mounted  
in 85% glycerol. 
 
2.1.20 Alizarin red in whole mount fish 
 
This technique was used to analyze bone in 6dpf fish. Larvae were fixed for 1 h at room 
temperature in 4% PFA in PBS, washed in 50% ethanol and dehydrated overnight in 95% 
ethanol. Staining was carried out in Alizarin solution (0.25%, w/v, in 2% KOH) for 3 h 
and larvae were then briefly cleared in 2% KOH (w/v) and stored in KOH/glycerol (20 : 
80). 
 
2.1.21 Alizarin red staining in vivo 
 
This technique was used to analyze  the mineralization of zebrafish bones in vivo. Fish 
were put in fish water added with Alizarin-3-methyliminodiacetic acid for 3 hours at 
28°C without light. 
 
2.1.22 In vivo lysosomal analysis 
 
Control and Ids ATG morpholinos, were coinjected in one-cell stage embryos with 
hsp70-Lamp1-RFP, a plasmid carrying the cDNA for the lysosomal membrane protein 
Lamp1 and  the cDNA encoding the fluorescent protein RFP. The transcriptional 
regulation of the expression cassette was under the control of a heat-shock inducible 
promoter. The plasmid was used to in vivo label lysosomes allowing to verify their 
number, and morphological alterations at different conditions. 
 
2.1.23 RNA extraction 
 
Total RNA was extracted from pools of fifty  zebrafish mutants, WT or morphants. The 
phenol/guanidine isothiocyanate extraction method (Trizol®, Lifetechnologies) was 
performed. In order to eliminate any genomic contamination, a DNase treatment was 
carried out in all RNA samples. 
 RNA were reverse transcribed into cDNA using the SuperScript® III Reverse 
Transcriptase (Invitrogen) kit . 
 
2.1.24 Real time PCR analysis  
 
This technique is used to precisely quantify transcripts levels of a target gene, using a 
fluorescent dye (Syber-Green) which is incorporated during the process of PCR 
amplification 
Transcripts levels of a target gene are generally normalized by comparison with those of 
endogenous housekeeping genes.  
Data were analyzed using a manually set threshold and the baseline was set automatically  
to obtain the threshold cycle (Ct) value for each target. Relative gene expression among 
samples was determined using the comparative Ct method (2  Ct). 
Primer used for the PCR reaction were designed using Primer3 program
http://primer3.ut.ee).  
The housekeeping gene chosen during this research study was: glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) 
For zebrafish were used primer that amplify transcripts of GFP, pea3, erk1, erm1 and 
gapdh genes (Table 9). 
 
Zebrafish 
Gene 
Primer RefSeq 
GFP For TAAACGGCCACAAGTTCAGC Published (Berkovits & Mayr, 2015) 
GFP Rev AAGTCGTGCTGCTTCATGTG Published (Berkovits & Mayr, 2015) 
pea3For CGATGAGCAGTTTGTTCCTG NM_131425 
pea3 Rev CTTGTGGCTGCAGGACTG NM_131425 
erk1For TGACCCTGAACATGACCACA NM_201507 
erk1 Rev GGTCCAGATAGTGCTTCCCA NM_201507 
erm1For TGTTCCAGATTTCCAGTCGG NM_001309209 
erm1 Rev AGTCTCTGCTCTTGTCCACA NM_001309209 
gapdh For GTGCAGGAGGCATTGCTTACA NM_001115114 
gapdh Rev GTGGAGTCTACTGGTGTCTTC NM_001115114 
Table 9: Primers used for Real time PCR analysis of Zebrafish samples. 
 
 
 
 
 
2.2 MOUSE 
 
2.2.1 Alcian blue Alizarin red staining in whole mount mice 
 
This staining was used to analyze cartilage and bone tissues in Ids-KO and WT mice. 
Mice were sacrificed and skin and organs were removed. Fixation was carried out in 95% 
ethanol for 5 days. Samples were washed with water and stained with 1% Alcian blue at 
pH 1.0 for 3 days. Mice samples were refixed with 95% ethanol overnight and put in 1% 
KOH solution for 5 days. After several washes with water, a solution of Alizarin red 1% 
pH 4.2 was added for 5 days. Samples were washed with 1% KOH and stored in glycerol.  
 
2.2.2 Alcian blue-Nuclear fast red staining  
 
This technique was used to analyze glicosaminoglycans accumulation in liver . 
Tissue sections were deparaffinized with xilene and rehydrated with ethanol solutions of 
decreasing concentration . After several washes with distilled water and  0,1M Citric acid 
was added to the samples for 3 minutes. Sections were stained with 1% pH 1.0 Alcian 
blue for 20 minutes. After several washes with distilled water, a Nuclear fast red solution 
was added to the samples for 10 minutes. Sections were washed and dehydrated with 
ethanol solutions of increasing concentration.    
 
2.2.3  Paraffin-embedding and sectioning 
 
Mouse samples were fixed in 4% PFA in PBS, washed in PBS and dehydrated in  ethanol 
solutions of increasing concentrations. Before dehydratation, mice bones were decalcified 
using a solution of 10% EDTA in PBS and samples were dehydrated in xylene. All 
solutions were removed and substituted with paraffin. Sectioning was performed using a 
microtome and tissue sections were collected on Superfrost slides. 
 
2.2.4 Immunohystochemistry 
 
Immunohystochemistry analysis was carried out on paraffinized sections. Paraffin-
embedded sections were deparaffinized with xilene and progressively rehydratated with 
ethanol solutions. Antigen retrieval was achieved with 1mM pH6.0 Sodium Citrate using 
a steam chamber. The primary antibody (PEA3, GeneTex) (COL2A1, Santa Cruz) 
(Osteocalcin, Santa Cruz) was incubated overnight at 4°C, while the secondary antibody 
(Goat anti rabbit-Alkaline Phosphatase, Sigma) was incubated 1 hour at room 
temperature and NBT-BCIP staining was performed.  
  
2.2.5 RNA extraction 
 
Total RNA was extracted from 1 week and 2 weeks old mouse samples, including the 
cranial vault, femur diaphysis and femur epiphysis. The phenol/guanidine isothiocyanate 
extraction method (Trizol®, Lifetechnologies) was performed. In order to eliminate any 
genomic contamination, a DNase treatment was carried out in all RNA samples. 
 RNA were reverse transcribed into cDNA using the SuperScript® III Reverse 
Transcriptase (Invitrogen) kit . 
2.2.6 Real time PCR analysis  
 
This technique has been described in 2.1.24 paragraph. 
Mice cDNA was reverse transcripted from RNA extracted from cranial vault, femur 
diaphysis and femur epiphysis samples of 1 week and 2 weeks knockout and WT mice. 
The housekeeping gene chosen during this research study was: beta-2-microglobulin 
(B2M). 
For mice were used primer that amplify transcripts of collagene 2 (Col2a1), osteocalcin, 
collagene X (Col10a1), interluchine1  (IL1 , TNF , pea3, erk1, dusp6 and b2m genes 
(Table 10). 
 
Mouse Gene Primer RefSeq 
collagene 2 For AAGGGTCACAGAGGTTACCC NM_031163 
collagene 2 Rev GTCCTCTCTCACCAGGCAG NM_031163 
osteocalcin For GAGGGCAATAAGGTAGTGAACAGA NM_007541 
osteocalcin Rev AAGCCATACTGGTTTGATAGCTCG NM_007541 
collagene X For ATGCTGAACGGTACCAAACG NM_009925 
collagene X Rev GGAATGCCTTGTTCTCCTCT NM_009925 
 For ACCTGTGTCTTTCCCGTGGAC Published (Chen et al., 2015) 
 Rev GGGAACGTCACACACCAGCA Published (Chen et al., 2015) 
 For AGCCCACGTCGTAGCAAACC Published (Chen et al., 2015) 
 Rev CATCGGCTGGCACCACTAGT Published (Chen et al., 2015) 
pea3For CCTTCTGCAGCAAATCTCCC NM_001316365 
pea3 Rev CTGCTCATCACTGTCCGGTA NM_001316365 
erk1For TACGGCATGGTCAGCTCAG NM_011952 
erk1Rev AGGATGTCTCGGATGCCTATAA NM_011952 
dusp6For ATGCGGGCGAGTTCAAATAC NM_026268 
dusp6Rev CAAGCAATGCACCAGGACAC NM_026268 
b2m For CGGCCTGTATGCTATCCAGA NM_009735 
b2m Rev ATTTCAATGTGAGGCGGGTG NM_009735 
Table 10: Primers used for Real time PCR analysis of mouse samples. 
 
 
2.3 HUMAN 
 
2.3.1 Real time PCR analysis  
 
This technique has been described in 2.1.24 paragraph. 
Human cDNA was obtained from RNA extracted from Hunter syndrome patients or 
healthy controls. Anonymized samples were obtained from Biobank of Genova Institute 
G. Gaslini. 
The housekeeping gene chosen during this research study was: glyceraldehydes-3-
phosphate dehydrogenase (GAPDH). 
For human samples were used primer that amplify transcripts of dusp6, erk1, pea3 and 
gapdh genes (Table 11). 
 
Human Gene Primer  RefSeq 
dusp6For CGTTCTACCTGGAAGGTGGC NM_001946 
dusp6 Rev CCGAGGAAGAGTCAGAGCTG NM_001946 
erk1For CAACCACATTCTGGGCATCC NM_002746 
erk1 Rev CTTGGTCTTGGAGGGCAGAG NM_002746 
pea3For CTACACCTTCAGCAGCAAATCG NM_001079675 
pea3 Rev TCACTGTCTGGTACCTGAGCTTC NM_001079675 
gapdh For CGAGCCACATCGCTCAGAC NM_002046 
gapdh Rev ACAATATCCACTTTACCAGAGTTAAAAGC NM_002046 
Table 11: Primer used for Real time PCR analysis of human samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 AIM OF THE PROJECT 
 
Mucopolysaccharidosis type II (MPSII or Hunter syndrome) is a rare disease caused by 
mutations in the IDS gene, encoding for the lysosomal enzyme iduronate 2-sulfatase 
(IDS). IDS is involved in the catabolism of the glycosaminoglycans(GAGs) heparan and 
dermatan sulfate, and mutations altering its activity lead to substrates accumulation into 
the organelle. Pathological manifestations, caused by GAGs storage, include metabolic 
and functional alterations ultimately leading to cell death. 
Traditionally,  glicosaminoglycans accumulation has been considered the primary cause 
of pathological defects. However, recent experimental evidences suggest that the 
molecular pathogenesis could be more complex and that other cellular mechanisms may 
contribute to the disease onset. 
The aim of my PhD project was to expand the current knowledge on the pathogenesis of 
MPSII-related bone defects, by evaluating whether the loss of iduronate 2-sulfatase 
activity may lead to early developmental cell signaling alterations before the onset of 
lysosomal GAGs accumulation.  
To this purpose, a zebrafish model for MPSII was generated and characterized at a 
molecular level, thus allowing to screen for candidate target signaling pathways affected 
by IDS loss of function. 
The second part of the PhD project was then focused on the molecular characterization of 
a candidate pathway in a murine model of Hunter syndrome, to assess whether the 
cascade of pathogenetic events detected in the fish model was conserved in a mammalian 
system. 
Finally, in the last part of the research project my investigation aimed at establishing in 
fibroblasts obtained from a selected cohort of Hunter syndrome patients whether the 
candidate signaling pathway defects may be related to the degree of disease severity.  
 
 
 
 
 
 
 
 
 
 
 
4 RESULTS 
 
4.1 Iduronate 2-sulfatase expression in zebrafish bones 
 
I have used zebrafish as animal model to analyze how IDS functional alterations lead to 
the pathological skeletal phenotype in Hunter syndrome. 
It has been previously shown that iduronate 2-sulfatase has an important role in 
development and ossification (Moro et al., 2010) (Mandal et al., 2013). However, the 
precise mechanisms involved in the IDS-dependent control of bone development are 
currently unknown. I began to analyze Ids expression in the bone compartment during 
development. To this purpose, I used the transgenic reporter line (Tg(Ola.Sp7:NLS-
GFP)zf132), in which the expression of the GFP reporter gene is driven by the osterix 
promoter, which is activated during osteoblast differentiation. In 5dpf transgenic fish, I 
performed a double immunohistochemistry using a primary antibody against GFP protein 
and a primary antibody against Ids protein. As expected Iduronate 2-sulfatase was largely 
expressed in the head, but with high level of expression in the cephalic bones. At 5dpf 
zebrafish the first cephalic bones, i.e. opercle, brachiostegal ray and cleithrum have 
formed (Fig. 18), and the double immunohystochemistry enabled me to detect 
colocalization between the GFP and Ids protein (Fig. 19 A-B-C).  
A highly magnified evaluation at confocal microscopy revealed a peculiar expression of 
the enzyme in the opercle. I found a consistent Ids expression in the proximal opercle 
region that is the most osteogenic zone (Fig. 19 D-E-F). In the brachiostegal ray, Ids was 
present in all the Osterix-positive regions (Fig. 19 G-J-K). In the cleithrum there was less 
colocalization between GFP and Ids, compared with the other bones. While Osterix was 
clearly expressed in the edges of the cleithrum, the enzyme was barely detectable in these 
regions while it was more expressed in the core region of the cleithrum (Fig. 19 H-I-L). 
These results show that Iduronate 2-sulfatase enzyme is expressed in osteogenic regions 
supporting its active role in bone development. 
 
Figure 18: (A) 5dpf zebrafish, the red 
square show the head region analyzed 
with the double immunohistochemistry.  
(B) Zebrafish head and a picture that 
show the localization of first ossificated 
bones.  
br: brachiostegal ray; cl: cleithrum; op: 
opercle.  
A 
B 
 
Figure 19: Double immunohystochemistry in 5dpf Osterix transgenic reporter line. In 
green GFP protein and in red Iduronate 2-sulfatase enzyme are shown. (A-B-C) Ids 
enzyme is largely expressed in zebrafish head and it colocalizes with GFP protein. (D-E-
F) High magnification of the opercle. Iduronate 2-sulfatase is present especially in the 
distal regions of the opercle that are the most osteogenic parts of the bone. (G-J-K) High 
magnification of the brachiostegal ray. There is full colocalization of Ids protein and GFP 
expression. (H-I-L) High magnification of the cleithrum. Osterix is expressed only in the 
dorsal tip of the cleithrum while Ids show only a weak colocalization with the bone 
marker. The enzyme is present also in central part of the cleithurm. Images taken with 
confocal microscope with 20x and 40x (high magnification) lens. br: brachiostegal ray; 
cl: cleithrum; op: opercle. 
 
 
 
4.2 Morpholino-based Ids knock down (KD) in zebrafish 
 
I have used a zebrafish model for Mucopolysaccharidosis type II obtained with the 
microinjection of a translation initiation-blocking morpholino oligo designed for the ids 
transcript. This model has been already described and partially characterized (Moro et al., 
2010). Morphant fish have been previously shown to display a decreased Iduronate 2-
sulfatase activity (Fig. 20 A) and a high embryonic mortality which is partially rescued by 
coinjecting the morpholino with the human recombinant IDS protein, Elaprase (Fig. 20 
B). 
 
Figure 20: (A) Ids-KD morphants exhibit lower enzyme activity when compared with 
control fish. (B) Embryonic  mortality rate is higher in morphant when compared with 
control fish and it is partially rescued by coinjecting the morpholino with the recombinant 
enzyme Elaprase. Image modified from (Moro et al., 2010). 
 
4.2.1 Characterization of the Ids-KD morphant  
 
I performed Western blot analysis in order to detect Ids protein levels in morphant fish 
and compared them with that of control fish. Ids-KD fish demonstrated a significant 
decrease in IDS protein levels when compared with mismatched morpholino-injected 
controls (Fig. 21). As I expected, the morpholino was not able to completely block ids 
translation, but the residual amount of enzyme was very low when compared with 
control. 
Since hepatomegaly is one of the main pathological alterations in Hunter patients, I 
analyzed liver morphology in morphant fish. Ids-KD fish from 6dpf displayed increased 
liver size when compared with controls. I used a transgenic reporter line 
Tg(lfabf:dsRed;elaA:EGFP), also called Lipan, that express the fluorescent protein dsRed 
under the control of a liver specific promoter and the fluorescent protein EGFP under the 
control of a pancreas specific promoter. This transgenic line permits to in vivo observe 
zebrafish liver using a fluorescent microscope. Using an in silico analysis, based upon the 
use of ImageJ-processed confocal acquisitions, I found that at 6dpf the Ids-KD liver is 
statistically significant bigger when compared to the control one (Fig. 22). Moreover, the 
difference between morphant and control liver size increased at 10dpf (Fig. 22) (Fig. 23). 
Alcian blue staining of paraffinized liver tissue sections from 10dpf larva showed 
accumulation of GAGs in morphant liver, that was not detectable in control samples (Fig. 
24). 
 
 
 
6dpf 10dpf 
Mean Standard deviation p-value Mean 
Standard 
deviation p-value 
Control   3945,9 409,3 
0,031 
  3041,1 557,0 
0,005 
Ids-KD   4443,9 767,4   4001,6 1112,1 
Figure 22: Increased liver volume size in 6dpf (A) and 10dpf (B) Ids-KD fish when 
compared with control fish. (C) Mean liver volume of  6dpf and 10dpf Ids-KD and 
control fish, analysis assessed in 15 fish for each group. Numbers in Y-axis are defined as 
arbitrary units. T-test analysis shows that the differences between morphant and control 
organ size are statistically significant (* p<0,05; **p<0,02). 
 
Figure 21: Representative Western blot 
analysis of three independent experiments. 
Ids-KD morphants show a significant knock 
down of Iduronate 2-sulfatase protein 
compared with controls. 
Figure 23: Rappresentative Ids-KD 
and control livers in Lipan 
transgenic line. 
notice the increased area of the 
morphant organ when compared 
with the control liver. 
A B 
C 
  
 
I was then interested to know whether morphants are characterized by alterations in 
lysosomal morphology and whether any GAGs accumulation is detectable also in fish. So 
I coinjected the translation initiation-blocking morpholino and the control morpholino 
with a heat shock-inducible Lamp1-RFP plasmid. Lamp1 is a lysosomal membrane 
protein and the  expression of this chimeric fusion protein enables to detect lysosomal 
morphology in living fish. I, therefore, analyzed several injected embryos at different 
developmental stages and I observed that the first lysosomal alterations are visible from 
3dpf in Ids-KD fish. In particular, 3dpf morphant fish exhibit a reduced number of 
lysosomes, with impaired morphology and cellular localization (Fig. 25 A) when 
compared with control fish (Fig. 25 B). Moreover some trunk epithelial cells in Ids-KD 
fish show abnormal shape when compared with controls (Fig. 25 C-D). 
 
 
Figure 24: Alcian blue staining 
of paraffinized sections, a 
representative 10dpf larva liver 
(A)(B). Morphants display 
GAGs accumulation in the liver 
(D) that is not present in 
controls (C). Images: A and C: 
sagittal (A->P) sections; B and 
D: transversal (V->D) sections. 
Figure 25: Representative 
confocal acquisition of Ids-KD 
fish and controls injected with 
a plasmid encoding for a 
Lamp1 protein fused in frame 
with RFP fluorescent protein. 
Morphant fish exhibit some 
altered cells with abnormal 
lysosomes (B-D) that are not 
detected in controls (A-C). 
4.2.2 Ids-KD fish display early ossification defects 
 
I used a zebrafish reporter line for Sox10 (Sox10:mRFP), that is a marker of migrating 
cranial neural crest cells that differentiate in osteoblasts and chondroblasts. I injected one 
cell-stage embryos for this reporter line with the translation initiation-blocking 
morpholino for ids or mismatch control morpholino. Fluorescence analysis showed a 
down regulation of the Sox10:mRFP transgene, in 1 dpf Ids-KD fish when compared with 
age-matched controls (Fig. 26 A-B). These data were also confirmed with in situ 
hybridizations using a probe against the fluorescent protein (Fig. 26 C-D).   
I also performed in situ hybridizations in 2dpf and 3dpf zebrafish morphant and control 
larvae for runx2b and collagenX bone markers. Runx2b is expressed at early stages of 
ossification in both cartilage and bone primordia. CollagenX is expressed during both 
intermediate and mature stages of osteoblast differentiation. At 2dpf runx2b was 
expressed in the opercle, brachiostegal ray and ceratobranchial arch 5. I found an 
increased expression of this marker in all examined bone elements of Ids-KD fish when 
compared with control fish (Fig. 27 A-B). CollagenX probe labels the opercle and 
cleithrum bones in 3dpf larvae. When comparing Ids-KD fish with controls I found that 
collagenX was similarly expressed in the cleithrum, while in the opercle its expression 
was reduced in morphants (Fig. 27 C-D).  
These results show that Ids has a key role in the very early stages of ossification and Ids-
KD fish display alterations in bone markers expression at 2dpf and 3dpf before any 
detectable lysosomal impairment.  
Moreover, morphants exhibit abnormal head cartilage morphogenesis, as shown by 
evident morphological alterations detected by Alcian blue staining (Fig. 28 A-B). Using 
Alizarin staining I was able to observe also ossification defects in Ids-KD (Fig. 28 C-D). 
 
 
 
 
Figure 27: In situ hybridization analysis show an up regulation of runx2b marker in 2dpf 
Ids-KD fish (B) compared to controls (A). Three independent experiments have been 
performed. collagenX expression in 
3dpf Ids-KD fish opercle (D) when compared with controls (C). br: brachiostegal ray; 
cb5:ceratobranchial arch 5; cl:cleithrum; op: opercle. 
 
 
Figure 26: Sox10:mRFP 
transgenic line injected with 
ids morpholino and 
mismatched morpholino. 
Fluorescent analysis show a 
downregulation of Sox10 in 
Ids-KD (B) fish compared 
to controls (A). This result 
is confirmed by in situ 
hybidrization using a probe 
against RFP fluorescent 
protein (C-D). 
 
Figure 28: Alcian blue staining analysis display altered cartilage morphogenesis in the 
head of 5dpf morphants (A-B). Alizarin red staining show an impaired bone development 
in 6dpf Ids-KD fish (C-D). 15 fish have been analyzed for each group. bh: basihyal;  
 
 
4.2.3 FGF signaling is impaired in Ids-KD fish 
 
To assess downstream pathways affected by Ids loss of function I injected the translation 
initiation-blocking morpholino for ids in a set of transgenic reporter fish for Wnt, , 
BMP, SHH, Notch and FGF signaling.  In repeated independent experiments I found an 
upregulation of the FGF signaling reporter line (Tg(dusp6:d2GFP)pt6) in 2 dpf morphant 
fish when compared with controls, both using fluorescence analysis approach (Fig. 29 A-
B) and in situ hybridization by means of a antisense riboprobe against the GFP 
fluorescent protein (Fig. 29 C-D). 
To validate my observations, I also performed several quantitative real-time PCR analysis 
for GFP in pooled 2dpf FGF transgenic reporter line injected with the morpholino and 
mismatch control morpholino. As shown in Fig. 30, I found an up regulation of the 
fluorescent protein expression in Ids-KD compared with controls, that correspond to FGF 
signaling up regulation. Using the same quantitative RQ-PCR, I also analyzed the 
expression of some FGF signaling markers: pea3, erk1 and erm1, in morphant and control 
samples. In independent experiments I was able to find a statistically significant up-
regulation of these markers in Ids-KD compared with controls (Fig. 31 A-C). 
Using pools of 6dpf zebrafish larvae injected with both the morpholino and control 
morpholino samples, I was able to find that the FGF reporter activity was consistently 
upregulated at 6dpf (Fig. 30), In agreement with these observations, pea3 and erm1 
expression were still significantly higher in morphants, when compared with pooled 
control samples, while erk1 transcripts were reduced at the same stage (Fig. 31 B-D). 
These results showed a dysregulation of FGF signaling in morphants in the early stages of 
development that is maintained during time. 
To further validate these results I performed in situ hybridization analysis with antisense 
riboprobes against the FGF targets, pea3, ntl and spry4, FGF ligands fgf3 and fgf8 and 
FGF receptor fgfr3. 
As shown in Fig. 32 and 33, I found an up regulation of fgfr3, fgf3, ntl and spry4 
transcripts in 1dpf Ids-KD fish compared to controls, and an up regulation of fgf8 and 
pea3 transcripts in 2dpf morphants compared to age-matched fish injected with 
mismatched morpholino. 
These results confirmed the data obtained by quantitative real time PCR analysis and 
showed that FGF signaling targets are more expressed in morphants fish in respect with 
control (Fig. 32 and 33).   
 
 
Figure 29: The transgenic line Tg(Dusp6:d2EGFP)pt6 injected with morpholino against 
ids ATG or with a mismatched morpholino, show an upregulation of FGF signaling in 
morphants (A) when compared with controls (B). This result was confirmed by in situ 
hybridization using a probe against GFP transcript (C,D). Three independent experiments 
have been performed. 
 
 
 
 
 
 
 
Figure 30: Real time PCR analysis performed on pool samples of 50 fish, from 2dpf and 
6dpf Tg(Dusp6:d2GFP)pt6 fish injected with the morpholino or mismatch control 
morpholino. Data are expressed as a mean of four independent experiments. In Ids-KD 
there is a significant reporter gene upregulation, in morphants at both 2dpf and 6dpf, 
when compared with age-matched controls. (t-test; * p<0,05). 
 
 
 
 
 
 
 
 
GFP 
 Mean 
Standard 
deviation p-value 
Control 1 / / 
Ids-KD 
2dpf 2,73 1,02 0,041 
Ids-KD 
6dpf 2,39 0,63 0,022 
A 
B 
Zebrafish 2dpf 
 Mean 
Standard 
deviation p-value 
Control 1 / / 
Ids-KD 
pea3 2,07 0,13 0,005 
Ids-KD 
erk1 1,73 0,41 0,016 
Ids-KD 
erm1 1,72 0,50 0,028 
 
Figure 31: Real time PCR analysis performed on pool samples of 50 Ids-KD fish or 
control fish at 2dpf and 6dpf. (A) (C) At 2dpf it was possible to see increased expression 
of pea3, erk1 and erm1 in Ids-KD compared with controls. (B) (D) At 6dpf morphant fish 
show up-regulation of pea3 and erm1 transcripts and a down regulation of erk1 
transcripts, when compared with age-matched  controls. Data are expressed as a mean of 
four independent experiments. T-test analysis was performed for each marker (* p<0,05; 
**p<0,02). 
 
 
Figure 32
possible to detect increased expression of fgfr3 (A,B), fgf3 (C,D) and fgf8 (E,F) 
transcripts in morphants when compared with age-matched controls. Three independent 
experiments have been performed. fv: forebrain ventricular zone; pe: pharyngeal 
endoderm; rb: rhombomere boundaries; t: telencephalon; vd: ventral diencephalon
 
Zebrafish 6dpf 
 Mean 
Standard 
deviation p-value 
Control 1 / / 
Ids-KD 
pea3 1,46 0,30 0,026 
Ids.KD 
erk1 0,83 0,06 0,012 
Ids-KD 
erm1 1,77 / / 
C D 
 
Figure 33: In situ hybridization enabled the analysis of FGF signaling markers affected by 
pea3 (A,B), ntl (C,D) 
and spry4 (E,F) transcripts in morphants when compared with age-matched controls. 
Three independent experiments have been performed. dd: dorsal diencephalon; mhb: 
midbrain hindbrain boundary; n: neuromast; no: notochord; pf: pectoral fin; t: 
telencephalon
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Zebrafish morphant with alternative ids splicing 
Using a custom pre-designed splicing sit-blocking morpholino I have generated an 
alternative fish model with a transient loss of Ids function. The morpholino targets the 
splice acceptor site between exon2 and intron2 of the ids gene.  
 
4.3.1 Zebrafish splicing morphant characterization 
 
Using gel electrophoresis analysis, I first verified the specificity of the splicing site-
blocking morpholino. To this purpose, I amplified the region containing the splicing site 
in cDNA obtained from RNA extracted from morphants or controls and I compared the 
results. Fish injected with a mismatched morpholino display an intense high molecular 
weight band other two bands of weak intensity. As shown in Fig.34, morphant extracts 
display the high molecular band with a weaker intensity. Morphant fish injected with 
splicing site-blocking morpholino exhibit  a better phenotype and a minor mortality rate 
when compared with  morphant injected with translation initiation-blocking morpholino 
(data not shown).  
 
 
Figure 34: Electrophoresis gel analysis of splicing variants in fish injected with splicing 
site-blocking morpholino or mismatched morpholino. Morphants show a high number of 
alternatively spliced transcript variants when compared with controls. 
 
4.3.2 FGF signaling analysis in Ids splicing morphants  
 
Given the previous observations that translation-initiation blocking morpholino for Ids 
produced a dysregulation of the FGF pathway, I decided to verify whether FGF reporter 
activity could be similarly affected by the splicing-blocking morpholino using the 
reporter line  (Tg(Dusp6:d2EGFP)pt6). Morphant fish displayed a reduction of  reporter 
fluorescence when compared with mismatch control (Fig. 35 A-B). This result was also 
confirmed by in situ hybridization using a riboprobe against GFP transcript (Fig. 35 C-
D).  
Quantitative Real time PCR analysis in whole morphant lysates did not show any obvious 
difference in the amount of GFP transcripts between morphants and controls (Fig. 36). 
Moreover there was no altered expression of FGF signaling markers pea3, erk1 and erm1, 
in fish injected with the splicing-blocking morpholino, when compared with fish injected 
with the mismatch morpholino (Fig. 36). 
 
 
Figure 35: The transgenic line Tg(Dusp6:d2EGFP)pt6 injected with splicing morpholino 
or with a mismatched morpholino, show a down regulation of FGF signaling in 
morphants (B) when compared with mismatch controls (A). Representative  
Tg(Dusp6:d2EGFP)pt6 larva  after in situ hybridization using a riboprobe against GFP 
transcript (C-D). Three independent experiments have been performed. A modest 
decrease in reporter expression is visible in morphants 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 36: Quantitative Real time PCR analysis performed on pool of 50 
Tg(Dusp6:d2GFP)pt6 fish at 2dpf, injected with the splicing morpholino or mismatched 
morpholino. Data are expressed as a mean of four independent experiments. There are no 
statistically differences between morphants and control in terms of GFP and FGF 
signaling markers expression. (t-test analysis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zebrafish 2dpf 
  Mean 
Standard 
deviation p-value 
Control 1 / / 
Ids-KD 
GFP 
0,90 0,35 0,630 
Ids-KD 
pea3 1,14 0,18 0,262 
Ids-KD 
erk1 1,27 0,38 0,294 
Ids-KD 
erm1 1,18 0,24 0,270 
 
4.4 Zebrafish Ids-/- mutant 
 
The transient morpholino-based knockdown model suffers from limited applicability to 
translational studies, due to the generation of an incomplete enzymatic deficiency and the 
restricted temporal activity of the morpholino itself, thus, hampering any investigation at 
late life stages. In order to evaluate the downstream effects of a complete loss of Ids 
function and to study the pathological alterations in adult fish, I created a stable mutant 
zebrafish line for the ids gene using the Crispr/Cas9 technology.  
This new tool for genome editing can target and modify specific gene loci with high 
efficiency, leading to the rapid creation of zebrafish mutants.  
 
4.4.1 Generation of a mutant zebrafish model for Mucopolysaccharidosis 
type II 
 
To generate a full loss of Ids function fish model,  I selected a target sequence in one of 
the first two exons of the Ids coding sequence. Mutations lying in the most proximal 
coding regions have an higher chance of destroying the active site, changing the 
frameshift and creating a premature stop codon. 
To this purpose, I chose a target sequence in the first part of exon 2, generating a mutant 
fish with a 5 bp deletion (sequence CTACT) from nucleotide 241 to nucleotide 245 (Fig. 
37). This deletion causes a frameshift, altering the protein sequence from aminoacid 82 
and leading to the generation of a premature stop codon at the aminoacid in position 118 
(Fig. 38).  
The mutated protein has some characteristics that make this zebrafish mutant a good 
candidate model for MPSII: 
- Deleted aminoacids are highly evolutionary conserved and have an important role for 
Ids enzymatic activity.   
-Since the deletion is located near the active aminoacid Cystein 78, it has a high chance of  
influencing the active site conformation or change the ligand affinity.  
-Early stop codon causes a truncated protein that may alter protein modification and 
enzymatic function.  
Figure 37: Alignment between the mutated sequence (MS) and the reference sequence of 
a wild type gene (RS). The mutated sequence has been amplified in the region of the 
deletion and sequenced using a reverse primer. Underlined in red is labeled the target 
sequence, with the deletion of 5 bp. 
 
 
Figure 38: A Truncated Ids protein is produced by the Crispr/Cas9  application. 
Highlighted in red is the target sequence without the five nucleotides. From aminoacid 82 
the sequence is altered and the red arrow shows the premature stop codon at aminoacid 
position 118. 
 
4.4.2 Enzymatic assay of mutated Iduronate 2-sulfatase 
 
To evaluate the enzymatic activity in homozygous mutant (Ids-/-) fish, an enzymatic assay 
in 2dpf Ids-/- larvae was performed and results were compared with that of age-matched 
heterozygous Ids+/- and WT fish. 
As shown in Fig. 39, homozygous mutants, obtained from an incross breeding among Ids-
/- fish, exhibited reduced enzymatic activity that was decreased  to 2% of that of wild type 
fish. Since the measured activity is close to the lowest sensitivity threshold of the assay it 
is plausible that the produced deletion has completely abolished enzymatic activity. It is 
interesting to notice that heterozygous fish generated from a cross between homozygous 
female mutants and WT males, have the same enzymatic activity of homozygous fish. On 
the contrary, heterozygous fish obtained from a cross between WT females and 
homozygous male mutants have a 60% reduction of enzymatic activity when compared to 
age-matched WT (Fig. 39). These data may support the idea  that at 2dpf the maternal ids 
MS 
RS 
transcripts are still present in zebrafish larvae and contribute for almost half of the 
detected Ids activity. 
The same activity assay was also performed in 3 months-old homozygous, heterozygous 
and WT fish organs (brain, liver and muscle). In all examined organs of Ids-/- fish there 
was no detectable enzyme activity. On the contrary, Ids+/- fish exhibited the same 
Iduronate 2-sulfatase activity of WT fish at the brain and muscle level, but half liver 
enzymatic activity when compared with age-matched control tissues (Fig. 40).  
 
Figure 39: (A) Graphic representation of Iduronate 2-sulfatase activity in 2dpf WT, 
homozygous mutants and heterozygous fish. Ids-/- homozygous mutant and heterozygous 
fish obtained from incross between homozygous mutant females and WT males almost do 
not  have  enzymatic activity. Ids+/- fish obtained from a cross between homozygous 
males and WT females display almost half enzymatic activity, when compared with age-
matched WT fish. (B) Mean enzymatic activity of 2dpf WT, homozygous fish Ids-/-, 
heterozygous fish Ids+/- obtained from cross between homozygous females and wt males 
or between wt females and homozygous males. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activity 
mean 
Standard 
Deviation 
WT  86,02 13,66 
Ids-/-  1,79 0,22 
Ids+/- from 
homozygous female  
1,81 0,13 
Ids+/- from 
homozygous male  
51,89 6,87 
A B 
 WT (3 months) Ids
-/- (3 months) Ids+/- (3 months) 
 Liver Brain Muscle Liver Brain Muscle Liver Brain Muscle 
Activity 
mean 
4,24 2,90 1,93 0,62 0,72 0,45 2,35 2,87 1,97 
Standard 
deviation 
0,09 0,06 0,64 0,26 0,52 0,14 0,03 1,10 0,66 
 
 
Figure 40: (A) Mean enzymatic activity of Iduronate 2-sulfatase in liver, brain and 
muscle of 3 months-old WT, homozygous Ids-/- and heterozygous Ids +/- fish. (B) Graphic 
representation of Iduronate 2-sulfatase activity in organs of 3 months WT, homozygous 
Ids-/- and heterozygous Ids+/- fish. The red line represent the assay sensitivity; values 
under the line may  
 
4.4.3 Ids-/- mutant fish characterization  
 
Mutant fish have the same growth rate of wild type fish in the first week, but they show 
an increased size (almost 12%) at 15dpf (Fig. 41 A-B). Mutants also display altered head 
formation with the presence of a bending on the midbrain (Fig. 41 C-D). 
Adult Ids-/- 
their easy identification. In adult mutant fish only a dorsal and ventral swelling can be 
detected (Fig. 41). Homozygous fish can reach sexual maturity and produce offspring; 
however they exhibit a shorter lifespan when compared with wild type siblings.   
At 3 months of age Ids-/- mutant fish show increased liver size and volume when 
compared with age-matched wild type fish (Fig. 42).  
A 
B 
 
 
 
  
4.4.4 Homozygous mutant fish display altered ossification at 6dpf and 15dpf 
 
To evaluate the downstream effects of Ids loss of function on bone formation, I 
performed Alizarin red staining in 6dpf and 15dpf Ids-/- mutant and age-matched wild 
type fish. Ids-/- mutant fish at 6dpf showed increased Alizarin staining of bone elements, 
when compared with age-matched wild type fish. A different shape and size of some bone 
elements was noticeable in Ids-/- mutant fish. For instance, the opercle in the proximal 
region appeared bigger when compared with the one of age-matched wild type fish (Fig. 
43). A further increased Alizarin staining of bone elements was detected on 15dpf Ids-/- 
mutant fish (Fig. 44), supporting the hypothesis that at early stages of development in 
mutant fish  bone mineralization occurs more rapidly when compared  with age-matched 
wild type fish.  
 
Figure 41: (A-B) Whole-mount 
15dpf WT (A) and Ids-/- fish (B). 
Ids-/- fish display a bigger length 
and size when compared with 
age-matched control fish. The 
bottom line shows the different 
length. (C-D) High magnification 
of the WT (C) and Ids-/- (D) head. 
The arrow indicates the bending 
on midbrain in mutant fish. 
A B 
C D 
Figure 42: (A-B) Whole mount 3 
months  WT fish (A) and Ids-/- 
fish (B) . (C-D) Representative 
liver from 3-month-old control 
fish (C) and Ids-/- fish (D), 
showing the enlarged liver size in 
the homozygous mutant.  
 
 
 
 
4.4.5 Reporter zebrafish lines for bone markers 
 
To evaluate the effects of Ids functional impairment on the bone differentiation program, 
I took advantage of specific transgenic fish lines Tg(Col2a1aBAC:mCherry)hu5900, 
TgBAC(col10a1:Citrine)hu7050 and Tg(Ola.Sp7:NLS-GFP)zf132. These transgenic fish 
express a fluorescent protein under the control of cartilage/bone cell lineage-specific 
promoters. In particular, I put  homozygous mutants in transgene background and I 
analyzed the offspring from incrossed transgenic mutant carriers. 
 
4.4.5.1 Collagen II expression in Ids-/- mutant fish 
 
Transgene expression was evaluated in Tg(Col2a1aBAC:mCherry)hu5900 at four time 
points: 4dpf, 7dpf (Fig. 45), 11dpf and 15dpf (Fig. 46). 
Figure 43: Alizarin red staining in 
6dpf WT fish and Ids-/- fish. (A-B) 
Lateral head view with opercle high 
magnification. (C-D) High 
magnification of the  parasphenoid. 
Homozygous fish (B) (D) display 
increased mineralization when 
compared with age-matched control 
fish (A) (C). Top images are lateral 
view, with anterior to the left, while 
bottom images are dorsal view with 
anterior to the left. 
Figure 44: Alizarin red staining in 
15dpf WT fish and Ids-/- fish. (A-B) 
Lateral head view with opercle high 
magnification. (C-D) Dorsal head 
view with parasphenoid high 
magnification. Homozygous fish (B) 
(D) display a major ossification 
compared to age-matched control 
fish (A) (C). Top images are lateral 
view, with anterior to the left, while 
bottom images are dorsal view with 
anterior to the left.
In particular, confocal analysis of fluorescent reporter protein expression  in the 
homozygous and age-matched wild type siblings, was carried out. Since Collagen II is 
expressed by chondrocytes, the amount of reporter protein in 
Tg(Col2a1aBAC:mCherry)hu5900 reflected the amount of cartilage. 
Ceratohyal cartilage: This cartilage is a component of the branchial arch. At 4dpf there 
was difference between WT and mutant fish. However, at 7dpf it  was possible to notice a 
rapid increase of cartilage volume in Ids-/- fish and the difference was statistically 
significant when compared to wild type control fish. Mutant fish displayed a rapid 
decrease of  ceratohyal cartilage volume between 7dpf and 11dpf and the final cartilage 
volume in mutants was smaller when compared with age-matched WT controls (Fig. 47). 
Palatoquadrate cartilage: This is a dorsal component of the mandibular arch. Mutant 
fish showed increased cartilage volume at 7dpf when compared with age-matched 
controls, and the difference was statistically significant. At 4dpf, 11dpf and 15dpf, Ids-/- 
exhibited  a similar cartilage volume when compared with age-matched WT fish (Fig. 
48). 
: 
demonstrated the same cartilage volume of control fish at 4dpf and 11dpf. However, Ids-/- 
showed a statistically significant increased volume at 7dpf and decreased volume value at 
15dpf, respectively, when compared with age-matched control fish (Fig. 49). 
Basihyal cartilage -/- fish 
showed the same cartilage volume at 4dpf. Control fish showed an almost linear increase 
in cartilage volume up to 15dpf, while mutant fish demonstrated a rapid increase of the 
volume between 4dpf and 7dpf and a decrease from 7dpf and 15dpf (Fig. 50). 
Summarizing, these results showed that while WT fish displayed a linear growth of the 
cartilages volume from 4dpf to 15dpf, mutant Ids-/- fish cartilage elements developed with 
a different trend that was the same for all the analyzed cartilages. There were no 
differences in the cartilage volume between mutant fish and controls at 4dpf, but at 7dpf 
Ids-/- fish showed a statistically significant rapid increase of cartilage volume. From 7dpf 
to 11dpf there was indeed a rapid decrease of cartilage volume in mutant fish which was 
consistently kept reduced at later life stages, i.e. from 11dpf to 15dpf . 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Representative image 
of a 4 dpf (top) and 7 dpf 
(bottom) wild type and Ids 
mutant 
Tg(Col2a1aBAC:mCherry)hu5900 
fish. Ids-/- fish display increased 
fluorescence when compared 
with age-matched controls. bh: 
basihyal; ch: ceratohyal; m: 
palatoquadrate. All images are 
ventral views, with anterior to 
the left. 
Figure 46: Representative image 
of a 11 dpf (top) and 15 dpf 
(bottom) wild type and Ids mutant 
Tg(Col2a1aBAC:mCherry)hu5900 
fish. bh: basihyal; ch: ceratohyal; 
palatoquadrate. All images are 
ventral views, with anterior to the 
left. 
Ceratohyal (ch) 
  4dpf   7dpf   11dpf   15dpf 
                        
  WT Ids-/-   WT Ids-/-   WT Ids-/-   WT Ids-/- 
Mean ( 3) 219183 210809   259782 317325   278898 261526   288963 262965 
Standard 
deviation 30665 28641   40798 28240   71514 37857   42748 32256 
p value 0,578   0,019   0,502   0,148 
 
 
 
Palatoquadrate (pq) 
  4dpf   7dpf   11dpf   15dpf 
                        
  WT Ids-/-   WT Ids-/-   WT Ids-/-   WT Ids-/- 
3) 143579 121579   209599 263114   224325 235145   247079 247977 
Standard 
deviation 38269 35923   11813 36950   75389 25006   34642 64178 
p value 0,3108   0,0053   0,7217   0,9776 
 
 
 
 
 
Figure 47: Mean Imaris-
calculated volume of 
Collagen II transgene 
expression in the 
ceratohyal cartilage of 
4dpf, 7dpf, 11dpf and 
15dpf zebrafish Ids-/- 
mutant and WT. (t-test 
**p<0,02).
Figure 48: Mean Imaris-
calculated volume of 
Collagen II transgene 
expression in the 
palatoquadrate cartilage of 
4dpf, 7dpf, 11dpf and 15dpf 
zebrafish Ids-/- mutant and 
age-matched WT. (t-test 
**p<0,02).
 
Meckel's cartilage (m) 
  4dpf   7dpf   11dpf   15dpf 
                        
  WT Ids-/-   WT Ids-/-   WT Ids-/-   WT Ids-/- 
3) 108507 104244   155718 176688   146756 140800   164330 143951 
Standard 
deviation 14947 22918   12769 8813   52355 25868   25922 23064 
p value 0,6477   0,006   0,7293   0,1004 
 
 
 
Basihyal (bh) 
  4dpf   7dpf   11dpf   15dpf 
                        
  WT Ids-/-   WT Ids-/-   WT Ids-/-   WT Ids-/- 
3) 39948 45956   54531 117506   52040 68934   77938 61356 
Standard 
deviation 19731 23933   20764 31125   34128 12174   30706 24873 
p value 0,6981   0,0434   0,2841   0,3727 
 
 
 
 
 
Figure 49: Mean Imaris-
calculated volume of 
Collagen II transgene 
expression in the 
4dpf, 7dpf, 11dpf and 
15dpf zebrafish Ids-/- 
mutant and age-matched 
WT. (t-test **p<0,02).
Figure 50: Mean Imaris-
calculated volume of 
Collagen II transgene 
expression in the basihyal 
cartilage of 4dpf, 7dpf, 11dpf 
and 15dpf zebrafish Ids-/- 
mutant and WT. (t-test 
*p<0,05).
To evaluate potential head developmental abnormalities  occurring in Ids-/- mutants, I 
performed in silico analysis of the distance between the  palatoquadrate cartilages, the 
hese two 
values, and the angle between the left and the right ceratohyal cartilages in agreement 
with a previous investigation  (Fig. 51) (Petrey et al., 2012). 
As regards the distance between palatoquadrate cartilages (PQ-PQ) I obtained the 
following results: at 4 dpf mutant fish display a smaller PQ-PQ distance when compared 
with age-matched WT. This parameter similarly increased up to  7dpf,  while from 7dpf 
to 11dpf the distance between palatoquadrate cartilages increased in Ids-/- fish and 
decreased in WT fish. From 11dpf to 15dpf the distance indeed decreased in Ids-/- fish and 
increased in WT fish, reaching the same value at 15dpf (Fig. 52). This data represent the 
head width thus suggesting a different rate of head development between WT fish and 
Ids-/- fish.  
M-CH): 
I detected a similar  increased distance in Ids-/- and WT fish from 4 dpf to 11 dpf. From 
11dpf to  15dpf, WT fish demonstrated an increased M-CH  distance while Ids-/- did not 
display any changes (Fig. 53). Therefore, while the head length was linearly growing in 
WT fish, mutant fish showed a growth arrest from 11dpf. 
When considering the ratio between the PQ-PQ distance and the M-CH  distance WT fish 
and mutant fish displayed a different behavior from 4dpf to 15dpf. The ratio value 
decreased in a linear way in WT fish, while Ids-/- fish showed a more rapid decrease from 
4dpf to 7dpf and a slower decrease from 7dpf to 15dpf when compared with age-matched 
WT controls (Fig. 54). 
Concerning the angle between the left and the right ceratohyals (CH to CH angle): WT 
fish and Ids-/- fish displayed a different trend. WT fish showed a linear decrease in the 
angle value from 4dpf to 15dpf. On the contrary, mutant fish exhibited a decreased angle 
size from 4dpf to 7dpf, an increased size from 7dpf to 11dpf and then a decreased angle 
size from 11dpf to 15dpf (Fig. 55). 
 
 
 
 
Figure 51: Representation of 
parameters analyzed. PQ: 
palatoquadrate cartilage, CH: 
ceratohyal cartilage, M: 
Image 
modified from Petrey et al., 
2012. 
 
PQ-PQ  
 
  4dpf  7dpf 
  Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   327156 17220,80 
0,120 
  343389 10237,89 
0,565 
Ids-/-   311671 3465,63   347151 2295,27 
 
 11dpf  15dpf 
 Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   327161 33975,33 
0,107 
  334340 16336,71 
0,989 
Ids-/-   353826 20189,43   334578 30572,41 
 
     
 
M-CH 
 
  4dpf  7dpf 
  Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   158759 23265,86 
0,783 
  191214 12944 
0,087 
Ids-/-   154359 25115,41   207180 2687,68 
 
 11dpf  15dpf 
 Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   210688 23101,37 
0,230 
  245334 15948,98 
0,068 
Ids-/-   225799 19776,10   225640 13454,78 
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Figure 52: Distance 
between palatoquadrate 
cartilages in Ids-/- and WT 
fish at 4dpf, 7dpf, 11dpf 
and 15dpf. Values in the Y-
axis are expressed as 
arbitrary units.  
 
 
PQ-PQ / M-CH 
 
  4dpf  7dpf 
  Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   2,08 0,20 
0,783 
  1,80 0,11 
0,358 
Ids-/-   2,07 0,42   1,68 0,03 
 
 11dpf  15dpf 
 Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   1,56 0,12 
0,777 
  1,37 0,07 
0,381 
Ids-/-   1,57 0,10   1,48 0,13 
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Figure 53: Distance between 
ceratohyal cartilage in Ids-/- 
and WT fish  at 4dpf, 7dpf, 
11dpf and 15dpf. Values in 
the Y-axis are expressed as 
arbitrary units. 
Figure 54: Ratio between the 
PQ-PQ/ distance and the M-
CH distance  in Ids-/- and WT 
fish  at 4dpf, 7dpf, 11dpf and 
15dpf. Values in the Y-axis 
are expressed as arbitrary 
units. 
CH to CH angle 
 
  4dpf  7dpf 
  Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   78,48 5,73 
0,377 
  64,00 11,01 
0,461 
Ids-/-   89,94 16,27   60,21 2,05 
 11dpf  15dpf 
 Mean Standard deviation p-value  Mean Standard deviation p-value 
WT   57,95 12,81 
0,412 
  53,67 2,89 
0,672 
Ids-/-   63,53 6,99   53,42 7,08 
4.4.5.2 Collagen X expression in Ids-/- mutant fish  
 
To analyze  collagen X expression in WT fish and Ids-/- fish I took advantage of the 
transgenic reporter line TgBAC(col10a1:Citrine)hu7050. Homozygous mutant and age-
matched wild  type transgenic fish were stained in vivo with Alizarin red, to evaluate the 
extent of bone mineralization together with Collagen X expression during bone 
development. CollagenX is expressed in hypertrophic chondrocytes and it is involved in 
matrix mineralization (Shen et al., 2005). 
To this purpose I examined three bones: opercle, cleithrum and brachiostegal ray at two 
time points of development: 7dpf and 15dpf. 
At 7dpf and 15dpf WT fish display a reduced number of cells expressing the collagen X 
transgene compared to age-matched Ids-/- fish.  However, the signal intensity appeared 
stronger in WT when compared with mutant fish in all analyzed bones. The opercle was 
the bone that showed more differences in signal intensity between mutant and WT fish. In 
Ids-/- fish collagen X was expressed in all bone surfaces and particulary in the opercle 
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Figure 55: Angle between 
the left and the right 
ceratohyals in Ids-/- and WT 
fish at  4dpf, 7dpf, 11dpf 
and 15dpf. Values in the Y-
axis are expressed as 
arbitrary units. 
proximal region, which is the most osteogenic region of the opercle. On the contrary, WT 
fish showed a lower collagen X expression.  
In WT fish, cleithrum displayed more collagen X-expressing cells, especially in the upper 
and lower ends of the bone, while in Ids-/- cleithrum  the signal was evenly expressed 
(Fig. 56 and 57 A, D). 
Alizarin red staining was more intense in WT fish opercle when compared with the 
mutant fish one. However, the staining in the mutant fish opercle was spread in a larger 
surface when compared with the WT fish one (Fig. 56 and 57 B, E). 
Further in silico-based analysis of CollagenX expression demonstrated that at 7dpf 
collagen X is generally more expressed in mutant fish bones, when compared with those 
of age-matched controls. In the brachiostegal ray the degree of increased expression, 
e ree time (Fig. 58) higher, while in the opercle 
(Fig. 59) and in the cleithrum is two time and half time higher (Fig. 60) in Ids-/- fish 
respectively, when compared with age-matched WT fish. At 15dpf there were no 
differences in Collagen X expression in mutant fish and WT fish bones (Fig. 58, 59 and 
60).  
To further evaluate other potential differences in bone development between mutant fish 
and WT fish, I examined the in-silico reconstruction of collagen X expression profile in 
the opercle. At 7dpf Ids-/- fish opercle display on average a different opercle shape and an 
increased area of collagen X expression when compared with WT opercle. In mutant fish 
the opercle proximal region size is increased and has a shape that is expected at later 
stages. At 15dpf the Ids-/- opercle maintain a different shape when compared with the WT 
opercle, with a swelling of its proximal part (Fig. 61). Since collagen X is expressed by 
osteoblasts that in turn release mineralized matrix and induce bone growth, an increased 
amount of this marker expression induces a more rapid increased rate of ossification. 
Therefore, 7dpf mutant fish exhibit a rapid increase in bone development which is 
reduced at later stages, while WT fish display a linear increase in the opercle growth. 
 
 
Figure 56: TgBAC(col10a1:Citrine) hu7050 Ids-/- fish and WT control stained in vivo with 
Alizarin red. (A, D) At 7dpf WT fish display a reduced number of cells that express 
CollagenX when compared with  Ids-/- fish, but in WT the signal is stronger than in 
mutants. (B, E) Alizarin red staining is stronger in WT fish when compared with  
mutants. br: brachiostegal ray; cl: cleithrum; op: opercle.  
 
 
Figure 57: TgBAC(col10a1:Citrine)hu7050    Ids-/- fish and WT controls stained in vivo with 
Alizarin red. (A, D) At 15dpf WT fish display a reduced number of cells collagenX-
expressing cells compared to Ids-/- fish, but in WT the signal is stronger than in mutants. 
(B, E) Alizarin red staining is stronger in WT fish compared to mutants. br: brachiostegal 
ray; cl: cleithrum; op: opercle. 
Opercle (Collagen X) 
 7dpf  15dpf 
 WT Ids
-/-  WT Ids
-/- 
3) 47181 87187  39106 28163 
Standard deviation 26274 32075  14863 
29118 
p-value 0,1019  0,4856 
Brachiostegal ray (Collagen X) 
 7dpf  15dpf 
 WT Ids
-/-  WT Ids
-/- 
3) 10590 30347  9673 9298 
Standard deviation 7321 13641  5618 
0 
p-value 0,0434   
Figure 58: Volume of 
collagenX expression in the 
brachiostegal ray of 7dpf and 
15dpf Ids-/- and WT 
transgenics. At 7dpf there is a 
statistically significant  increase 
of collagen X volume 
expression in mutants when 
compared with age-matched 
WT fish. (t-test *p<0,05).
Figure 59: CollagenX 
expression in the opercle of 
7dpf and 15dpf Ids-/- and age-
macthed WT fish . At 7dpf a 
light but not significantly 
increased volume of collagen X  
expression is detected in 
mutants when compared with 
age-matched WT.
Cleithrum 
 7dpf  15dpf 
 WT Ids
-/-  WT Ids
-/- 
3) 50325 78141  15689 16515 
Standard deviation 7877 13384  5540 8080 
p-value 0,0116  
0,8724 
4.4.5.3 Osterix expression in Ids-/- mutant fish  
 
I used the transgenic reporter line Tg(sp7:EGFP)b1212 to analyze the expression of Osterix 
in WT fish and Ids-/- fish. Osterix is an osteoblast marker and it is required for osteoblast 
differentiation and bone formation (Baek et al., 2009). 
Figure 60: CollagenX expression 
in the cleithrum of 7dpf  15dpf 
Ids-/- and WT transgenics . At 
7dpf a statistically significant  
increase in collagen X expression 
volume is detected in mutants 
when compared with age-
matched WT. (t-test **p<0,02).
Figure 61: 
Collagen X expression. Ids 
mutants show a different 
opercle shape when compared 
with age-matched WT at 7dpf 
(A, B) and 15dpf (C, D). 
I studied Osterix expression in three bones: brachiostegal ray, opercle and cleithrum at 
7dpf and 15 dpf WT and Ids-/- fish. 
At 7dpf and 15dpf mutant fish display the same Osterix expression intensity of WT fish. 
However, the region of transgene expression in the brachiostegal ray and opercle of  
mutant fish appears wider when compared with control fish. Conversely, in the cleithrum 
a decreased fluorescence is observed in Ids-/- fish, when compared with age-matched WT 
fish (Fig. 62 and 63 A, D). 
By using an in silico approach to analyze transgene expression, I found that Ids mutant 
fish showed a statistically significant increased expression of Osterix in the brachiostegal 
ray and opercle at 7dpf when compared with age-matched controls, while similar 
transgene expression levels were detected in the same regions at 15dpf (Fig. 64 and 65). 
In the cleithrum there were no differences of osterix expression between WT and Ids-/- 
fish at 7dpf , while at 15dpf mutants displayed a statistically significant  decrease of 
osterix expression when compared with control fish (Fig. 66). 
To summarize, while  in both the opercle and brachiostegal ray of Ids mutants increased 
osterix transgene expression levels were detectable at 7dpf, the cleithrum was 
characterized by a significant decreased osterix expression at 15 dpf. To further evaluate 
changes in bone development caused by Ids loss of function, I analyzed, by in silico 
analysis, the opercle shape of Tg(sp7:EGFP)b1212 mutants and age-matched WT. At 7dpf 
mutants opercle displayed an increased size when compared with that of age-matched 
WT, especially in the proximal regions. At 15 dpf Ids-/- opercle appeared very similar to 
the bone of mutant fish at 7dpf (Fig. 67).  
 
 
 
Figure 62: Tg(sp7:EGFP)b1212 Ids-/- fish and controls stained in vivo with Alizarin red. (A, 
D) At 7dpf WT fish display a reduced number of Osterix-expressing cells when compared 
with age-matched Ids-/- fish, but in WT the signal is stronger than in mutants. (B, E) 
Alizarin red staining is stronger in WT fish compared to mutants. br: brachiostegal ray; 
cl: cleithrum; op: opercle. 
Figure 63: Tg(sp7:EGFP)b1212 Ids-/- fish and controls stained in vivo with Alizarin red. (A, 
D) At 7dpf WT fish display a reduced number of Osterix-express in cells when compared 
with age-matched Ids-/- fish. (B, E) Alizarin red staining is stronger in WT fish compared 
to mutants. br: brachiostegal ray; cl: cleithrum; op: opercle.
Brachiostegal ray (Osterix) 
 7dpf  15dpf 
 WT Ids
 -/-  WT Ids
 -/- 
3) 17836 34757  19347 17516 
Standard deviation 7217 6379  9503 4938 
p-value 0,0216  0,7818 
 
Opercle (Osterix) 
 7dpf  15dpf 
 WT Ids
 -/-  WT Ids
 -/- 
3) 41731 92159  100713 70102 
Standard deviation 29135 21332  28790 6701 
p-value 0,0315  
0,1473 
 
Figure 64: Osterix expression 
volume in brachiostegal ray of 
Ids-/- and WT fish. At 7dpf 
there is a statistical significant 
increase of osterix expression in 
mutants when compared with 
age-matched controls. At 15 dpf 
there are no differences between 
Ids-/- and WT. (t-test *p<0,05). 
Figure 65: Volume of Osterix 
expression in the opercle of Ids-/- 
and WT fish. At 7dpf there is a 
statistically significant increase 
of osterix expression in mutants 
when compared with controls. At 
15 dpf there are no differences 
between Ids-/- and WT. (t-test 
*p<0,05).
Cleithrum (Osterix) 
 7dpf  15dpf 
 WT Ids
 -/-  WT Ids
 -/- 
3) 70160 55469  51240 
24601 
Standard deviation 38145 19049  4917 5059 
p-value 0,5165  0,0028 
4.4.6 Ids-/- mutant fish display altered mineralization 
 
To analyze bone mineralization Alizarin staining have been performed in7dpf and 15dpf 
mutant fish and age-matched WT controls. Analysis of confocal images showed increased 
amount and  extent of bone mineralization  in Ids-/- fish (Fig. 56 B-E) (Fig. 57 B-E) (Fig. 
62 B-E) (Fig. 63 B-E). 
Figure 66: Volume of Osterix 
expression in cleithrum of Ids-/- 
and WT fish. At 7dpf there are 
no differences between Ids-/- and 
WT. At 15 dpf there is a 
statistically significant decrease 
of osterix expression in mutants 
when compared with age-
matched controls. (t-test 
**p<0,02). 
Figure 67: Osterix expression 
profile in the opercle of Ids-/- 
and WT fish. (A) (B) At 7dpf 
there is a larger transgene 
expression domain in the 
opercle of mutants when 
compared with that of age-
matched controls. (C) (D) At 
15dpf osterix expression 
appears increased in the opercle 
of  WT fish, while in  the  
mutants opercle the transgene 
expression domain appears 
slightly reduced. 
In particular, in silico analysis of Alizarin red staining volume in the brachiostegal ray, 
opercle and cleithrum was performed. Brachiostegal ray and opercle displayed  increased 
mineralization at 7dpf in mutant fish when compared with age-matched controls, while at 
15dpf no differences were observed (Fig. 68 and 69). In the cleithrum there was no 
difference at 7dpf, while bone mineralization decreased in Ids-/- fish at 15dpf when 
compared with age-matched WT (Fig. 70). 
The in silico reconstruction of Alizarin staining profile demonstrated a similar 
mineralized opercle area in mutants when  compared to that of control at 7dpf, while it 
increased in mutants at 15dpf. Ids-/- fish displayed also an altered opercle shape at both 
7dpf and 15dpf when compared to that of controls. In particular mutant fish showed an 
increased proximal region of the opercle that appeared expanded when compared with 
that of WT  fish (Fig. 71). 
 
Brachiostegal ray (Alizarin) 
 7dpf  15dpf 
 WT Ids
 -/-  WT Ids
 -/- 
Volume Mean ( m3) 22671 36042  41214 36563 
Standard deviation 10339 3646  11339 5809 
p-value 0,0122  0,4611 
 
Figure 68: Alizarin red staining 
volume in the brachiostegal ray 
of Ids-/- and WT fish. At 7dpf 
there is a statistically significant 
increase in alizarin red  stained 
regions of the brachiostegal ray 
of mutants when compared with 
those of controls. At 15 dpf 
there are no differences between 
Ids-/- and WT fish. (t-test 
**p<0,02).
Opercle (Alizarin) 
 7dpf  15dpf 
 WT Ids
 -/-  WT Ids
 -/- 
3) 61488 102332  123385 
100512 
Standard deviation 27996 12579  28993 32212 
p-value 0,0073  0,2293 
Cleithrum (Alizarin) 
 7dpf  15dpf 
 WT Ids
 -/-  WT Ids
 -/- 
3) 50050 54895  50991 
32779 
Standard deviation 23578 23434  19176 12414 
p-value 0,7181  0,1129 
Figure 69: Alizarin red staining 
volume in the opercle of Ids-/- 
and WT fish. At 7dpf there is 
increased alizarin red  stained 
region of the opercle of mutants 
when compared to that of  
controls. At 15 dpf there are no 
differences between Ids-/- and 
WT fish. (t-test **p<0,02).
Figure 70: Alizarin red staining 
volume in the cleithrum of Ids-/- 
and WT fish. At 7dpf there are 
no differences between Ids-/- and 
WT. At 15 dpf there is an 
increased stained region of 
mutants cleithrum when 
compared to that of controls. 
4.4.7 FGF signaling dysregulation in Ids-/- mutant fish 
 
To verify whether changes in FGF signaling regulation could be responsible for bone 
differentiation and mineralization defects, I analyzed  Ids-/- mutant fish in the transgenic 
Tg(Dusp6:d2EGFP)pt6 background.  
Fluorescent microscopy analysis showed that homozygous mutant reporter fish exhibit an 
FGF signaling down regulation when compared to that of WT reporter fish (Fig. 72). 
Heterozygous reporter fish display a variable degree of FGF signaling activity, according 
to parental genetic background. In particular, heterozygous Ids+/- fish generated from the 
cross of homozygous female fish with WT males, showed a variable degree of 
fluorescence intensity when compared to age-matched control siblings (Fig. 73 A,B,C). 
Indeed, heterozygous Ids+/- fish obtained from the cross between WT female fish and 
homozygous males displayed instead a comparable FGF reporter transgene intensity 
when compared to WT (Fig. 73 D,E,F). To better quantify the extent of FGF reporter 
transgene differences between Ids-/- homozygous, heterozygous Ids+/- and control siblings, 
I performed real time PCR analysis on pooled samples of Tg(Dusp6:d2EGFP)pt6 fish in 
the different Ids background. Quantitative real time PCR analysis showed a significant 
reduction of GFP, pea3, erk1 and erm1 transcripts in homozygous fish when compared to 
age-matched controls (Fig. 74 and 75). 
Heterozygous fish obtained from the cross between homozygous Ids-/- female and WT 
males, showed a weak up regulation of GFP transcripts when compared with controls, 
Figure 71: Alizarin red staining  
profile in the opercle in 7dpf 
and 15dpf Ids-/- and WT fish. 
(A,B) At 7dpf mutant fish 
display an altered shaped, 
opercle when compared to the 
control one. (C,D) In 15dpf Ids-/- 
fish the mineralized opercle 
regions is bigger when 
compared to that of age-
matched controls
while the expression of  FGF signaling markers pea3, erk1 and erm1 were similar with 
that of WT. Heterozygous fish coming from the cross between WT female fish and 
homozygous males did not show any significant differences in the expression of GFP and 
FGF signaling markers transcripts when compared to age-matched WT (Fig 74 and 75). 
Figure 72:  Tg(Dusp6:d2EGFP)pt6 WT and Ids-/- fish at 2dpf. Mutant fish (A) display a 
decreased GFP expression when compared to that of WT (B). ot: otic vesicle, pe: 
pharyngeal endoderm, tg: trigeminal ganglia. 
Figure 73: Heterozygous fish show a vary variable GFP expression at 2dpf. (A,B,C) Ids+/- 
that coming from a cross between an homozygous female and a WT male show 
heterogeneous GFP expression. (D,E,F) Heterozygous fish coming  from a cross between 
a WT female and an homozygous male do not display any significant difference of GFP 
expression when compared to WT fish (Fig. 71A).  
Figure 74: Quantitative real time PCR analysis of FGF signaling reporter transgene in 
WT and Ids-/- fish at 2 dpf. Homozygous Ids mutant fish show a down regulation of 
reporter transgene  expression when compared with controls. Heterozygous coming from 
the cross between homozygous females and WT males show a weak up regulation of GFP 
transcripts when compared with controls. There are no differences in GFP expression 
between WT and heterozygous Ids+/-  fish coming from the cross between WT females 
and homozygous males. Data are expressed as a mean of four independent experiments.  
(t-test **p<0,02). 
 GFP 
 Ids
-/- 
Ids+/-  
from Ids-/- 
female 
Ids+/-  
from Ids-/- 
 male 
Mean 0,73 1,11 1,19 
Standard 
deviation 0,06 0,01 0,1 
p-value 0,018 0,002 0,084 
 pea3 
 Ids
-/- 
Ids+/-  
from Ids-/- 
female 
Ids+/-  
from Ids-/- 
male 
Mean 0,64 0,83 1,1 
Standard 
deviation 0,1 0,13 0,09 
p-value 0,025 0,151 0,198 
 erk1 
 Ids
-/- 
Ids+/-  
from Ids-/- 
female 
Ids+/- 
 from Ids-/- 
male 
Mean 0,72 0,85 0,91 
Standard 
deviation 0,03 0,15 0,16 
p-value 0,004 0,225 0,422 
Figure 75: Quantitative real time PCR analysis for pea3, erk1 and erm1 in WT and Ids-/- 
fish at 2 dpf. Homozygous fish show a down regulation of all markers expression when 
compared to controls, while no differences are seen betweenWT and heterozygous fish. 
Data are expressed as a mean of four independent experiments. (t-test *p<0,05; 
**p<0,02). 
 
 erm1 
 Ids
-/- 
Ids+/-  
from Ids-/- 
female 
Ids+/-  
from Ids-/- 
male 
Mean 0,82 0,95 0,95 
Standard 
deviation 0,07 0,07 / 
p-value 0,049 0,389 / 
4.5 Mouse model for Mucopolysaccharidosis type II 
 
All the experiments were performed in an already previously described mouse model for 
Hunter syndrome (Garcia et al., 2007). This mouse model has a deletion of exon 4 and 
part of exon 5 of the Ids gene leading to the transduction of a non-functional enzyme.  
All examined IDS-KO mice derived from an inbreeding between an homozygous female 
and an hemizygous male, and therefore the offspring was deprived of Ids maternal 
transcripts. Mice have been analyzed at different ages, from postnatal day 0 to 6 months. 
 
4.5.1 Characterization of IDS-KO mice 
 
Although widely previously characterized, IDS-KO mice were briefly examined in the 
present study to specifically ascertain parameters influencing our analysis, including body 
weight and GAG deposits, at several progressive time-points. I measured IDS-KO and 
WT mice body weight, from 1 week to 6 months. IDS-KO mice showed a statistically 
significant reduced  weight at 5 weeks when compared with age-matched WT. In all other 
examined time points there were  no statistically significant differences between the two 
groups (Fig. 76 and 77). 
To qualitatively assess the onset of glycosaminoglycans accumulation in the murine IDS-
KO,  I examined Alcian blue/nuclear fast red stained liver tissue sections from IDS-KO 
and age-matched WT siblings at different stages. There was no evident GAGs storage in 
1 week and 2 week  at 9 months Alcian-blue stained 
regions were evident in all KO liver tissue samples (Fig. 78). It was possible to notice 
glycosaminoglycans accumulation in IDS-KO mice liver from 8-10 weeks (data not 
shown). 
 
 
 
 
Figure 76: Ids-KO and WT mice body weight increases during development from 1 week 
to 6 months. At 5 weeks IDS-KO mice display a statistically significant  lower weigh 
than WT siblings. (t-test **p<0,02). 
 
 1 week  2 weeks 
 
Mean 
(gr) 
Standard 
deviation p-value  
Mean 
(gr) 
Standard 
deviation p-value 
WT 3,53 0,61 
0,798 
WT 7,83 0,50 
0,122 
IDS-KO 3,59 0,48 IDS-KO 7,20 1,41 
 5 weeks  10 weeks 
 
Mean 
(gr) 
Standard 
deviation p-value  
Mean 
(gr) 
Standard 
deviation p-value 
WT 15,52 2,25 
0,013 
WT 24,71 1,31 
0,182 
IDS-KO 12,68 1,85 IDS-KO 23,28 2,19 
 3 months  6 months 
 
Mean 
(gr) 
Standard 
deviation p-value  
Mean 
(gr) 
Standard 
deviation p-value 
WT 27,00 3,46 
1,000 
WT 32,00 1,73 
0,152 
IDS-KO 27,00 1,00 IDS-KO 34,00 1,41 
Figure 77: Mean body weight of IDS-KO and WT mice at 1week (11 WT mice and 11 
IDS-KO mice), 2weeks (14 WT mice and 16 IDS-KO mice), 5weeks (9 WT mice and 8 
IDS-KO mice), 10weeks (6 WT mice and 8 IDS-KO mice), 3 months (3 WT mice and 3 
IDS-KO mice) and 6months (3 WT mice and 4 IDS-KO mice). 
 
 
Figure 78: Alcian blue /nuclear fast red stained  liver sections from IDS-KO and age-
matched wild type mice. No GAGs accumulation was detectable in 1week (A-D) and 
2weeks (B-E) old WT and knockout mice. Indeed 9 months old IDS-KO (F) show a large 
accumulation of glycosaminoglycans (arrow) in the liver which is not detectable in age-
matched controls (C). 
 
4.5.2 IDS-KO mice show altered early craniofacial development 
 
To evaluate the onset of potential  ossification defects in IDS-KO mice, I analyzed the 
skull conformation in 1 week and 2 weeks old IDS-KO and WT mice. One week old 
knockout mice displayed a flatter skull when compared to that of age-matched WT 
siblings (Fig. 79 and 81), while at 2 weeks the skull height was significantly increased 
when compared to age-matched controls (Fig. 80 and 81). The skull length was not 
different  between knockout and WT mice at both ages (Fig. 81). Moreover, in two weeks 
old IDS-KO mice the skull was less vascularized when compared to that of age-matched 
WT mice (Fig. 80).  
To evaluate differences in the rate of skull ossification, multiple Alcian blue/Alizarin Red 
stained samples from Ids-KO and WT mice were examined at different ages. Figure 82 
shows the mouse skull organization, composed by frontal, parietal and interparietal bones 
that are intervened by metopic, coronal, sagittal and lamboid sutures (Fig. 82).  
One day old Ids-KO mice showed increased Alcian blue staining in the cranial sutures 
that appeared also characterized by an irregular shape when compared to those of age-
matched WT mice. Moreover, the interfrontal gap and lamboid sutures were wider in 
knockout mice when compared to those of WT controls (Fig. 83 A,B and 84 A,B). 
At postnatal stages, i.e. at one 1 week and 2 weeks, IDS-KO mice exhibited more jagged 
skull sutures when compared with age-matched WT siblings (Fig. 83 C,D) (Fig. 84 C,D) 
 (Fig. 83 E,F) (Fig. 84 E,F).  
At 3 months and 6 months IDS-KO mice demonstrated persistent Alcian blue stained 
cranial sutures which were not detectable in age-matched WT skull samples (Fig. 85).  
A skull size analysis was then performed in IDS-KO and WT mice at 1 day (4 WT mice 
and 6 IDS-KO mice), 1 week (5 WT mice and 5 IDS-KO mice), 2 weeks (6 WT mice and 
7 IDS-KO mice),  3 months (3 WT mice and 3 IDS-KO mice) and 6 months (3 WT mice 
and 4 IDS-KO mice) of age, according to the previously described parameters 
(Kawakami et al., 2008) (Fig. 86).  
Nasal length (NL): there were no differences during development between IDS-KO and 
WT mice (data not shown). 
Frontal bone length (FL): from 1 day to 2weeks there were no differences between IDS-
KO and WT mice, however at 3 months knockout mice showed a  statistically significant 
reduction of this parameter while at 6 months a statistically significant increased FL was 
detected in KO mice when compared to the control one (Fig. 87 A and 88). 
Parietal bone length (PL): there were no differences during development between IDS-
KO and WT mice (data not shown). 
Interparietal bone length (IL): IDS-KO mice showed a statistically significant 
reduction of this parameter at 1day compared to controls (Fig. 87 B). 
Nasal bone width (NW): there were no differences during development between IDS-
KO and WT mice (data not shown). 
Distance between left and right anterolateral corner of the frontal bone (LR): IDS-
KO mice displayed a statistically significant increase of this parameter at 6 months when 
compared to controls (Fig. 87 C and 88). 
Frontal bone width (FW): there were no differences during development between IDS-
KO and WT mice (data not shown). 
Interparietal bone width (IW): IDS-KO mice demonstrated a statistically significant 
increase of this parameter at 6 months when compared to controls (Fig. 87 D). 
 
Figure 79: 1 week IDS-KO (C,D) and WT mice skull (A,B). Knockout mice display an 
altered skull shape when compared to the WT skull. 
 
 
Figure 80: 2 weeks old IDS-KO (C,D) and WT (A,B) mice skull. IDS-KO mice skull (D) 
appears less vascularized when compared to the WT skull (B). 
 
 
 
 
 
A B 
1 week 
 
2 weeks 
  WT IDS-KO   WT IDS-KO 
Mean height 4,42 4,29 Mean height 5,36 5,63 
Standard deviation 0,05 0,03 Standard deviation 0,27 0,24 
p value 0,018 p value 0,026 
            
Mean lenght  8,72 8,42 Mean lenght 11,62 11,89 
Standard deviation 0,05 0,29 Standard deviation 0,27 0,27 
p value 0,157 p value 0,054 
Figure 81: IDS-KO mice show a reduced skull height at 1 week (A) and an increased 
skull height at 2 weeks (B) when compared with age-matched controls ( t test, *p<0,05; 
**p<0,02). 3 IDS-KO mice and 3 WT mice at 1 week and 10 IDS-KO mice and 10 WT 
mice at 2 weeks were been analyzed. 
 
 
 
 
Figure 83: Alcian blue  Alizarin red stained skulls of  1 day (A,B), 1 week (C,D) and 2 
weeks old (E,F) WT and IDS-KO mice. P0 knockout mice show wider gaps among 
sutures when  compared to control skulls. 1 week and 2 weeks old IDS-KO mice display 
irregular shaped  and incompletely closed skull sutures. 
Figure 82: Schematic representation of a murine skull 
two parietal bones and an interparietal bone. Bones are 
intervened by coronal, lambdoid, metopic and sagittal 
sutures. F: frontal bone, IP: interparietal bone; P: 
parietal bone. Image taken from (Deckelbaum et al., 
2006) 
C D 
 
Figure 84: Alcian blue - Alizarin red stained skull samples of 1 day (A,B), 1 week (C,D) 
and 2 weeks (E,F) old WT and IDS-KO mice. More jagged shaped skull sutures in the 
interparietal bone and Alcian blue  stained areas in the skull of knockout mice can be 
observed when compared to age-matched controls. 
 
 
Figure 85: Alcian blue - Alizarin red stained skull samples of 3 months (A,B) and 6 
months (C,D) old WT and IDS-KO mice. Marked Alcian blue staining is visible in IDS-
KO mice skull sutures. 
 
 
 
 
 
 
Figure 87: Graphical representation of measured skull bone parameters. For most 
measured parameters IDS-KO mice display a significant increase at 6 months of age. For 
only the IL parameter there is a statistically significant difference at 1 day post-partum 
between knockout and WT mice (t-test¸*p<0,05). FL: frontal bone length; IL: 
interparietal bone length; LR: distance between left and right anterolateral corner of 
frontal bone; IW: interparietal width.  
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Figure 86: Schematic representation of linear measurements of the 
cranium. Image taken from (Kawakami et al., 2008) 
NL: nasal bone length;  
FL: frontal bone length;  
PL: parietal bone length;  
IL: interparietal bone length;  
NW: nasal bone width;  
LR: distance between left and right anterolateral corner of the 
frontal bone;  
FW: frontal bone width; 
IW: interparetal bone width. 
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Figure 88: Alcian blue  Alizarin red stained skull samples of 3 months (A,B) and 6 
months (C,D) WT and IDS-KO mice. FL (frontal bone length) and LR (distance between 
left and right anterolateral corner of the frontal bone) are indicated. Increased Alcian blue 
staining in knockout mice sutures is detectable when compared to WT mice. 
 
 
4.5.3 IDS-KO mice show impaired long bones development  
 
Long bones are particularly affected in Hunter syndrome patients, displaying short bone 
length and enlarged diaphysis. I, therefore, examined tibia and femur length in 1 day (4 
WT mice and 6 IDS-KO mice), 1 week (5 WT mice and 5 IDS-KO mice), 2 weeks (6 WT 
mice and 7 IDS-KO mice),  3 months (3 WT mice and 3 IDS-KO mice) and 6 months (3 
WT mice and 4 IDS-KO mice) Ids-KO and WT mice.  
One day, 1 week and 2 weeks  old knock
and femur length when compared with age-matched WT mice (Fig. 89) (Fig. 91) (Fig. 92) 
(Fig. 94). IDS-KO mice started to show reduced tibia and femur length at 3 months when 
compared with age-matched WT mice and the bone length difference became statistically 
significant at 6 months (Fig. 90) (Fig. 91) (Fig. 93) (Fig. 94). 
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Figure 89: Representative  
tibial bone of 1 day (A,B), 1 
week (C,D) and 2 weeks (E,F) 
IDS-KO and WT mice. 
Figure 90: Representative tibial 
bone of 3 months (A,B) and 6 
months (C,D) IDS-KO and WT 
mice. 
Figure 91: Tibia growth in 
IDS-KO and WT mice from 
1day to 6 months. A 
statistically significant 
difference in tibia length is 
detectable at 6 months between 
IDS-KO and WT mice (t-test * 
p<0,05). 
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Figure 92: Representative 
femur bone of 1 day (A,B), 1 
week (C,D) and 2 weeks (E,F) 
IDS-KO and WT mice. 
Figure 93: Representative 
femur bone of 3 months (A,B) 
and 6 months (C,D) IDS-KO 
and WT mice. 
Figure 94: Femur growth in 
IDS-KO and WT mice from 
1day to 6 months. A 
statistically significant 
difference in femur length is 
detectable at 6 months between 
IDS-KO and WT mice. (t-test 
* p<0,05). 
4.5.4 IDS-KO mice show dysregulated expression of bone specific markers 
 
To analyze whether IDS loss of function was affecting the expression of bone-related 
markers in mice at early life stages histochemical analysis for Collagen II and Osteocalcin 
(OCN)  was carried out in tibial paraffin-embedded sections from 1 week and 2 weeks old 
Ids-KO and WT mice. 
While an in silico-based quantitative analysis of immunopositive cells did not show 
obvious difference between Ids-KO and WT mice (Fig. 97), immunoreactive cell types 
were different between the two groups. In particular, Collagen II in Ids-KO mice was 
highly expressed in the proliferating region of both 1 week and 2 weeks old mice, while 
in WT mice Collagen II immunopositive cells were equally distributed among the 
proliferating, prehypertrophic and hypertrophic zones (Fig. 95 A,B and 96 A,B). When 
considering Osteocalcin in 1 week Ids-KO mice, more immunopositive cells were 
detected in the proliferating and hypertrophic zones, while in age-matched WT  OCN-
positivity was observed in proliferating, prehypertrophic and hypertrophic zones (Fig. 95 
C,D). In two weeks old mice there was no difference in the distribution of 
immunopositive cells between WT and KO mice, as regards the three regions  (Fig. 96 
C,D). 
To quantitatively assess differences in the expression levels of bone-related markers 
between WT and KO mice, I performed quantitative real time PCR in RNA extracts 
obtained from the cranial vault, femur epiphysis and femur diaphysis of 1 week and 2 
weeks IDS-KO and WT mice. Collagen II, Osteocalcin and Collagen X were analyzed in 
pooled samples of the two groups. IDS-KO cranial vault samples showed a down-
regulation of Collagen X expression at 1 week and a down-regulation of Osteocalcin at 1 
week and 2 weeks, when compared to those of age-matched WT. No  differences between 
in the expression of Collagen 2 were detected between 1 week and 2 weeks old IDS-KO 
and WT mice cranial vault samples (Fig. 98 A,D) (Fig.99 A).  
When considering the femur diaphysis, an up regulation of Collagen II and down 
regulation of Collagen X expression was seen in both 1 week and 2 weeks Ids-KO when 
compared with age-matched WT samples. A down regulation of Osteocalcin was 
observed only in 1 week IDS-KO mice samples when compared to wild type ones (Fig. 
98 B, E) (Fig. 99 B). Femur epiphysis samples  showed indeed a down regulation of 
Collagen II and Osteocalcin in 2 weeks old knockout mice samples when compared to 
age-matched controls (Fig. 98 F) (Fig. 99 C).  
Since it is well known that activation of inflammatory pathway may contribute to the 
impaired bone development (Opoka-Winiarska et al., 2013), I analyzed the expression of 
and  in all bone samples from the two groups. 
 As shown in Fig. 100 and 101, no differences in  expression were measured in the 
cranial vault and epiphysis samples of both 1 week and 2 weeks old knockout mice when 
compared with age-matched control tissues. Indeed, diaphysis samples from 1 week and 2 
weeks old IDS-KO mice showed a down-regulation of  expression, when compared 
with age-matched WT mice diaphysis. No differences were detected in  expression 
between WT and knockout mice for all bone samples, but in 1 week old IDS-KO mice 
diaphysis and epiphysis samples a significant decrease of  was seen when compared 
with age-matched controls. 
 
 
Figure 95: Representative immunohistochemistry analysis for collagen II (A,B) and 
osteocalcin (C,D) performed in tibia samples of 1 week old IDS-KO and WT mice . A 
different localization of immupositive cells is seen in Ids-KO mice when compared with 
controls. pr: proliferating  zone, ph: prehypertrophic zone, h: hypertrophic zone. 
 
 
Figure 96: Representative immunohistochemistry analysis for collagen II (A,B) and 
osteocalcin (C,D) performed in tibia samples of 2 weeks old IDS-KO and WT mice. A 
different localization of immupositive cells is seen in IDS-KO mice when compared with 
controls. pr: proliferating  zone, ph: prehypertrophic zone, h: hypertrophic zone 
 
 
Figure 97: Integrated density quantification of collagen II and osteocalcin 
immunopositive cells in tibia sections. No statistically significant differences are detected 
between IDS-KO and WT mice. 
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Figure 98: Quantitative real time PCR analysis in 1 week and 2 weeks IDS-KO and WT 
mice cranial vault (A-B), diaphysis (C-D) and epiphysis (E-F) samples for Collagen II, 
Osteocalcin and Collagen X. (t-test ;*p<0,05; **p<0,02). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
E F 
Cranial vault  Diaphysis 
    Mean Standard deviation 
p 
value     Mean 
Standard 
deviation 
p 
value 
WT   1 / / WT   1 / / 
IDS-KO 
ColII 
1 
week 1,17 0,34 0,480 
IDS-KO 
ColII 
1 
week 2,28 0,67 0,032 
IDS-KO 
OCN 
1 
week 0,69 0,06 0,011 
IDS-KO 
OCN 
1 
week 0,58 0,08 0,011 
IDS-KO 
ColX 
1 
week 0,63 0,19 0,030 
IDS-KO 
ColX 
1 
week 0,65 0,14 0,015 
IDS-KO 
ColII 
2 
weeks 1,06 0,12 0,492 
IDS-KO 
ColII 
2 
weeks 4,89 2,02 0,031 
IDS-KO 
OCN 
2 
weeks 0,51 0,09 0,010 
IDS-KO 
OCN 
2 
weeks 1,06 0,23 0,088 
IDS-KO 
ColX 
2 
weeks 0,88 0,28 0,460 
IDS-KO 
ColX 
2 
weeks 0,33 0,24 0,045 
Epiphysis 
    Mean Standard deviation 
p 
value 
WT   1 / / 
IDS-KO 
ColII 
1 
week 0,85 0,20 0,315 
IDS-KO 
OCN 
1 
week 0,78 0,24 0,250 
IDS-KO 
ColX 
1 
week 0,74 0,51 0,472 
IDS-KO 
ColII 
2 
weeks 0,55 0,20 0,021 
IDS-KO 
OCN 
2 
weeks 0,44 0,31 0,035 
IDS-KO 
ColX 
2 
weeks 0,65 0,42 0,287 
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Figure 99: Quantitative real time PCR 
analysis in 1 week and 2 weeks old 
IDS-KO and WT mice cranial vault 
(A), diaphysis (B) and epiphysis (C) for 
ColII, OCN and ColX (t-test *p<0,05; 
**p<0,02). 
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Figure 100: Quantitative real time PCR analysis in 1 week and 2 weeks old IDS-KO and 
WT mice cranial vault (A,B), diaphysis (C,D) and epiphysis (E,F) for . (t-
test *p<0,05; **p<0,02; ***p<0,002). 
 
Cranial vault  Diaphysis 
    Mean Standard deviation 
p 
value     Mean 
Standard 
deviation 
p 
value 
WT   1 / / WT   1 / / 
IDS-KO 
 
1 
week 1,11 0,16 0,366 
IDS-KO 
 
1 
week 0,51 0,1 0,013 
IDS-KO 
 
1 
week 0,78 0,27 0,287 
IDS-KO 
 
1 
week 0,6 0,03 0,001 
IDS-KO 
 
2 
weeks 1,19 0,11 0,092 
IDS-KO 
 
2 
weeks 1,45 1,07 0,558 
IDS-KO 
 
2 
weeks 1,19 0,09 0,064 
IDS-KO 
 
2 
weeks 0,74 0,15 0,039 
Epiphysis 
    Mean Standard deviation 
p 
value 
WT   1 / / 
IDS-KO 
 
1 
week 0,67 0,12 0,042 
IDS-KO 
 
1 
week 0,88 0,17 0,325 
IDS-KO 
 
2 
weeks 0,73 0,15 0,094 
IDS-KO 
 
2 
weeks 0,7 0,21 0,063 
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Figure 101: Quantitative real time PCR 
analysis in 1 week and 2 weeks old 
IDS-KO and WT mice cranial vault 
(A), diaphysis (B) and epiphysis (C) for 
-test *p<0,05; 
**p<0,02; ***p<0,002). 
C 
4.5.5 IDS-KO mice show altered FGF signaling 
 
Given the impairment of  FGF signaling activity detected in the fish model, I evaluated 
whether IDS-KO mice showed any deregulation of this pathway. Immunohistochemical 
analysis for PEA3 performed in tibia samples of Ids-KO and WT mice showed an overall 
decrease of  PEA3 protein levels in 1 week old KO mice when compared with age-
matched WT (Fig. 104). Moreover, 1 week old IDS-KO mice showed PEA3-
immunopositivity in the prehypertrophic zones, while in WT mice immunopositive cells 
were detected in proliferating and prehypertrophic zones (Fig. 102). Concerning 2 weeks 
old IDS-KO and WT mice no differences in PEA3 expression were observed (Fig. 103). 
To better quantify differences in FGF signaling activity I performed quantitative real time 
PCR analysis for Pea3, Erk1 and Dusp6 in cranial vault, femur diaphysis and femur 
epiphysis samples of 1 week and 2 weeks old IDS-KO and WT mice. 
No differences in Pea3 and Dusp6 expression were detected in one week old cranial vault 
samples of IDS-KO and WT (Fig. 105 A) (Fig. 106 A). Similarly, no further significant 
discrepancies in terms of Pea3, Erk1 and Dusp6 expression were measured in cranial 
vault samples of the two groups at 2 weeks (Fig. 105 D) (Fig. 106 A). Indeed, one 1 week 
old KO-mice cranial vault samples showed a down-regulation of Erk1 transcripts when 
compared with controls (Fig. 105 A) (Fig. 106 A).  
As regards the diaphysis Pea3, Erk1 and Dusp6 expression was similar  between both 1 
week and 2 weeks old knockout and WT mice (Fig. 105 B, E) (Fig. 106 B). 
Concerning the epiphysis a significant down-regulation of Erk1 and Dusp6 expression 
and Pea3, Erk1 and Dusp6 transcripts was observed, in 1 week and 2 weeks old KO mice, 
respectively, when compared with age-matched WT (Fig. 105 C, F) (Fig. 106 C). 
To summarize, in all examined bone samples a significant decrease of FGF-related 
markers expression was detected in KO-mice, although with consistent differences 
according to the evaluated bone region. 
 
 
 
 
Figure 102: Representative immunohistochemistry for PEA3 in tibia samples of 1 week 
old IDS-KO and WT mice. A different signal distribution in detected in IDS-KO sections 
(B) when compared with controls (A). pr: proliferating  zone, ph: prehypertrophic zone, 
h: hypertrophic zone. 
 
 
Figure 103: Representative immunohistochemistry for  PEA3 in tibia samples of 2 weeks 
old IDS-KO and WT mice No differences are detected between IDS-KO (B) when 
compared with controls (A). pr: proliferating  zone, ph: prehypertrophic zone, h: 
hypertrophic zone. 
 
 
 
Figure 104: Integrated density quantification 
of PEA3 immunohistochemistry signal in 
tibia sections. Analysis were performed in 4 
WT mice and 4 IDS-KO mice samples of 1 
week and 2 weeks. A statistically significant 
reduction of PEA3 expression is seen in 1 
week IDS-KO mice when compared with 
age-matched WT mice (t-test; *p<0.05). 
Figure 105: Quantitative real time PCR analysis in 1 week and 2 weeks Ids-KO and WT 
mice samples of cranial vault (A,B), diaphysis (C,D) and epiphysis (E,F) for Pea3, Erk1 
and Dusp6 (t-test *p<0,05; **p<0,02; ***p<0,002). 
 
 
 
 
 
 
 
A B 
C D 
E F 
Cranial vault  Diaphysis 
    Mean Standard deviation 
p 
value     Mean 
Standard 
deviation 
p 
value 
WT   1 / / WT   1 / / 
IDS-KO 
Pea3 
1 
week 0,75 0,17 0,063 
IDS-KO 
Pea3 
1 
week 1,02 0,31 0,942 
IDS-KO 
Erk1 
1 
week 0,55 0,05 0,001 
IDS-KO 
Erk1 
1 
week 0,77 0,29 0,310 
IDS-KO 
Dusp6 
1 
week 0,88 0,22 0,349 
IDS-KO 
Dusp6 
1 
week 0,87 0,06 0,057 
IDS-KO 
Pea3 
2 
weeks 0,99 0,19 0,928 
IDS-KO 
Pea3 
2 
weeks 0,88 0,11 0,112 
IDS-KO 
Erk1 
2 
weeks 0,78 0,25 0,174 
IDS-KO 
Erk1 
2 
weeks 0,98 0,39 0,917 
IDS-KO 
Dusp6 
2 
weeks 0,99 0,17 0,914 
IDS-KO 
Dusp6 
2 
weeks 1,17 0,17 0,151 
Epiphysis 
    Mean Standard deviation 
p 
value 
WT   1 / / 
IDS-KO 
Pea3 
1 
week 0,52 0,02 0,020 
IDS-KO 
Erk1 
1 
week 0,57 0,10 0,017 
IDS-KO 
Dusp6 
1 
week 0,74 0,20 0,151 
IDS-KO 
Pea3 
2 
weeks 0,47 0,16 0,007 
IDS-KO 
Erk1 
2 
weeks 0,57 0,16 0,012 
IDS-KO 
Dusp6 
2 
weeks 0,55 0,27 0,043 
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Figure 106: Quantitative real time PCR 
analysis in 1 week and 2 weeks old 
IDS-KO and WT mice cranial vault 
(A), diaphysis (B) and epiphysis (C) for 
Pea3, Erk1 and Dusp6 (t-test *p<0,05; 
**p<0,02; ***p<0,002). 
C 
 
4.6 Mucopolysaccharidosis type II patient fibroblasts 
To understand whether an FGF signaling impairment could be a downstream effect due to 
IDS loss function in Hunter syndrome patients, I performed expression analysis of FGF-
specific markers in fibroblasts retrieved from a selected cohort of patients. Anonymized 
samples were obtained from Biobank of Genova Institute G. Gaslini. Fibroblast cDNA 
samples from affected patients harboring different iduronate 2-sulfatase mutations were 
subjected to transcriptomic analysis and results were compared with those of healthy 
control samples (Table 10). All samples were grouped according to the type of mutation 
(non-sense mutation, missense mutation or deletion) and the localization of the IDS 
mutation  (N-terminal or C-terminal) (Table 12). 
Next some information related to the mutations characterizing the fibroblasts used for the 
analysis are reported: 
P4Sfs: 
in position X43, leading to a truncated protein (Lualdi et al., 2010). 
R8X: This mutation causes the synthesis of a short polypeptide lacking the active site; 
however patients show a mild form of MPSII. It has been supposed that this stop codon 
may be occasionally skipped during transcription (Vafiadaki et al., 1998).  
W12X: Produces a short N-terminal part of the protein that has not functional activity 
(Kato et al., 2005). 
S 117: n in-frame deletion c.472delTCC causing the loss of a serine residue in  
position 117. The skipping of this aminoacidic residue the enzyme 
maturation, so it has been supposed that the mutated polypeptide has an altered ability to 
reach the lysosome (Bonuccelli et al., 2001). 
R88: Arginine 88 is highly conserved among sulfatases and human IDS structure analysis 
has revealed that this residue is important for the enzyme proper conformation. It is 
core of the major IDS 
domain. Mutations in this aminoacid can change the orientation of the secondary structure 
(Chkioua et al., 2011).  
R88H: Arginine and Histidine aminoacids are both positively charged, but the presence of 
an imidazole group in the Histidine residue can alter the enzyme structure and function 
(Balzano et al., 1998).  
R88P:  The substitution of Arginine with a Proline residue can alter the stability of the 
directly affect enzyme activity. The protein instability causes altered IDS function leading 
to a severe form of the disease (Chkioua et al., 2011). 
R443X: The truncated enzyme produced by this mutation has a residual enzymatic 
activity and decreased stability. This mutation is associated with an intermediate form of 
MPSII (Isogai et al., 1998). 
C422R: This mutation affects a non-conserved residue among human sulfatases, but it 
can be associated with a severe form of the pathology (Moreira da Silva et al., 2001). 
R468Q: This mutation could be a mutational hot spot because it is common in the 
Caucasian population (Isogai et al., 1998). 
This aminoacid is adjacent to the positively charged active site residue K347, forming 
together 
(Koji & Koji, 2005). R468Q mutation has been found in several patients with severe or 
intermediate phenotype (Sukegawa-Hayasaka et al., 2006). 
 
Patient Mutation Phenotype Kind of mutation Localization 
Control / Healthy / / 
H150 P4Sfs Mild 
Non-sense mutation 
N-terminal 
H147 R8X Mild 
H122 W12X Intermediate 
23-15 Q66X Intermediate 
37-15 Q80X Severe 
f23 Y103X Intermediate 
614/14  Intermediate/Severe Deletion 
616/14 N63D Intermediate 
Missense mutation 
15-15 R88H Severe 
f48 R88P Intermediate 
617/14 P120R Intermediate 
12-15 L279X Intermediate/Severe 
Non-sense mutation 
C-terminal 
9-15 L359X Mild 
1121-14 R443X Intermediate 
H148 C422R Mild/Intermediate 
Missense mutation 
H162 C422R Mild 
F24 P467L Mild 
H8 R468Q Severe 
13-15 R468Q Severe 
1124-14 R468Q Intermediate/Severe 
1122-14 R468Q Severe 
Table 12: List of analyzed patients samples displaying different mutations (non-sense, 
missense or deletion) in N-terminal or C-terminal part of the IDS gene. The phenotypic 
classification of each patient (mild, intermediate or severe) is also reported. 
Three FGF signaling-specific markers (DUSP6, ERK1 and PEA3)  were analyzed by RQ-
PCR for each sample and results were compared to those obtained from healthy control 
samples. 
Non-sense mutation N-terminal (Fig. 107):  
Patient H150 (P4Sfs mutation) shows a down regulation of DUSP6 and ERK1 and an up-
regulation of PEA3 transcripts levels when compared with controls. 
Patients H147 (R8X mutation) and f23 (Y103X mutation) display a down regulation of 
all markers when compared with control. 
Patient H122 (W12X mutation) shows an up regulation of all markers expression when 
compared with control. 
Patient 23-15 (Q66X mutation) displays an up regulation of DUSP6 and PEA3 and a 
down regulation of ERK1 transcripts levels when compared with controls. 
Patient 37-15 (Q80X mutation) shows a down regulation of DUSP6 and PEA3 transcripts 
levels when compared with controls. 
Deletion N-terminal (Fig. 108): 
DUSP6 and ERK1 and an 
up regulation of PEA3 transcripts levels when compared with controls. 
Missense mutation N-terminal (Fig. 109): 
Patients 616/14 (N63D mutation) and 617/14 (P120R mutation) show a down regulation 
of DUSP6 and ERK1and an up regulation of PEA3 transcripts when compared with 
controls. 
Patient f48 (R88P mutation) displays a down regulation of all markers expression when 
compared with controls. 
Patient 15-15 (R88H mutation) show a down regulation of DUSP6 and PEA3 transcripts 
when compared with controls. 
Non-sense mutation C-terminal (Fig. 110): 
Patient 12-15 (L279X mutation) shows a down regulation of DUSP6 transcripts when 
compared with controls. 
Patient 9-15 (L359X mutation) displays a down regulation of DUSP6 and PEA3 
transcripts expression when compared with controls. 
Patient 1121-14 (R443X mutation) exhibits an up regulation of DUSP6 transcripts when 
compared with controls . 
Missense mutation C-terminal (Fig. 111): 
Patients H148 (C422R mutation) and 1122-14 (R468Q mutation) display a down 
regulation of all markers when compared with controls. 
Patient H162 (C422R mutation) shows a down regulation of DUSP6 and ERK1 and an up 
regulation of PEA3 transcripts levels when compared with controls. 
Patient F24 (P467L mutation) displays a down regulation of DUSP6 and an up regulation 
of PEA3 transcript levels when compared with controls. 
Patients H8 (R468Q mutation) and 1124-14 (R468Q mutation) displays an up regulation 
of all markers expression when compared with controls 
Patient 13-15 (R468Q mutation) shows an up regulation of DUSP6 and ERK1 transcripts 
when compared with controls. 
Given the heterogeneous results detected when evaluating the same type of mutation, I 
tried to analyze the data considering patient phenotype (mild, intermediate and severe). 
All patients displaying a mild form of the disease (H150, H147, 9-15, H162, F24) 
exhibited a general down regulation of FGF signaling markers. 
Patient H148 that has a mild/intermediate form displayed a down regulation of all FGF 
signaling-related markers levels. 
Patients with an intermediate form of the disease showed down regulation (f23, 616/14, 
f48, 617/14) or up regulation (H122, 23-15, 1121-14) of FGF signaling-related markers 
expression. 
Among patients with the intermediate phenotype, all affected subjects displaying a down 
regulation of the FGF signaling markers were those harboring mutations in the N-
terminal part of IDS gene: 616/14, f48 and 617/14 display a missense mutation, f23 has a 
non sense mutation with a stop codon after the active residue Cys84.  
Among patients exhibiting an up regulation of the FGF signaling markers, H122 and 23-
15 were characterized by  a non-sense mutation and a stop codon before the active residue 
Cys84, respectively, while 1121-14 had a non sense mutation in the C-terminus. 
Patients 614/14 and 1124-14 displaying an intermediate/severe phenotype showed a down 
regulation (614/14) and an up regulation (1124-14) of the analyzed markers. 
Patients with a severe form of MPSII showed a down regulation (37-15, 15-15,1122-14) 
or an up regulation (H8, 13-15) of the analyzed FGF-signaling markers. 
Among affected patients exhibiting a severe phenotype those characterized by a down 
regulation of the FGF signaling markers harbor mutations in the N-terminal part of the 
IDS gene (37-15 and 15-15) or a missense mutation in the C-terminus (1122-14), while 
patients displaying an up regulation of the same markers were characterized by missense 
mutations in the C-terminus. 
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Figure 107: (B-D-F) Real time PCR analysis performed in patients with non-sense 
mutation in the N-terminal part of IDS gene, using DUSP6, ERK1 and PEA3 primers. The 
results were compared to unaffected control subjects. (A,C,E) Graphic representation of 
DUSP6, ERK1 and PEA3 expression in patients samples compared to unaffected subjects. 
Results are expressed as a mean ± SEM of four independent experiments. (* p<0,05; ** 
p<0,02; *** p<0,002; t-test).  
 
 
DUSP6 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
H150 P4Sfs 0,03 0,00 4,02E-06 
H147 R8X 0,00 0,00 6,17E-09 
H122 W12X 5,64 10,12 0,364 
23-15 Q66X 5,97 0,55 0,001 
37-15 Q80X 0,34 0,08 0,001 
f23 Y103X 0,41 0,13 0,003 
ERK1 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
H150 P4Sfs 0,86 0,41 6,08E-01 
H147 R8X 0,15 0,02 1,40E-04 
H122 W12X 8,65 1,95 0,004 
23-15 Q66X 0,76 0,12 0,028 
37-15 Q80X 1,13 0,32 0,466 
f23 Y103X 0,76 0,17 0,067 
PEA3 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
H150 P4Sfs 2,38 0,48 1,04E-02 
H147 R8X 0,50 0,05 3,59E-03 
H122 W12X 4,7 0,46 0,001 
23-15 Q66X 1,65 0,35 0,035 
37-15 Q80X 0,39 0,08 0,001 
f23 Y103X 0,37 0,06 0,000 
A B 
C D 
E F 
Deletion N-terminal 
 
 
 
DUSP6 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
614/14  0,00 0,00 8,10E-11 
 
ERK1 
Sample Mutation Mean Standard 
deviation 
p-value 
Control / 1 / / 
614/14  0,34 0,03 1,60E-05 
 
PEA3 
Sample Mutation Mean Standard 
deviation 
p-value 
Control / 1 / / 
614/14  3,16 0,43 2,00E-03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 108: Real time PCR analysis 
performed in a patient with deletion 
-terminal part of IDS 
gene, using DUSP6, ERK1 and PEA3 
primers. The results were compared to 
unaffected control subjects. (A,B,C) 
Graphic representation of DUSP6, 
ERK1 and PEA3 expression in patient 
samples compared to unaffected 
subjects. Results are expressed as a 
mean ± SEM of four independent 
experiments. (* p<0,05; ** p<0,02; 
*** p<0,002; t-test). (D,E,F) 
Expression mean, standard deviation 
and t test p-value. 
E 
D 
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Figure 109: (B,D,F) Real time PCR analysis performed in patients with missense 
mutation in the N-terminal part of IDS gene, using DUSP6, ERK1 and PEA3 primers. The 
results were compared to unaffected control subjects. (A,C,E) Graphic representation of 
DUSP6, ERK1 and PEA3 expression in patients samples compared to unaffected subjects. 
Results are expressed as a mean ± SEM of four independent experiments. (* p<0,05; ** 
p<0,02; *** p<0,002; t-test).  
 
 
DUSP6 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
616/14 N63D 0,05 0,09 0,001 
15-15 R88H 0,54 0,05 0,001 
f48 R88P 0,27 0,05 7,20E-05 
617/14 P120R 0,01 0,00 1,40E-08 
ERK1 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
616/14 N63D 0,47 0,09 0,002 
15-15 R88H 1,06 0,44 0,791 
f48 R88P 0,84 0,35 3,63E-01 
617/14 P120R 0,34 0,05 0,00E+00 
PEA3 
Sample Mutation Mean Standard 
deviation 
p-value 
Control / 1 / / 
616/14 N63D 2,76 0,66 0,013 
15-15 R88H 0,41 0,06 0,001 
f48 R88P 0,38 0,06 1,00E-03 
617/14 P120R 4,09 0,86 6,00E-03 
A 
C 
B 
D 
E 
F 
Non-sense mutation C-terminal 
 
 
 
 
Figure 110: (B,D,F) Real time PCR analysis performed in patients with non-sense 
mutation in the C-terminal part of IDS gene, using DUSP6, ERK1 and PEA3 primers. The 
results were compared to unaffected control subjects. (A,C,E) Graphic representation of 
DUSP6, ERK1 and PEA3 expression in patients samples compared to unaffected subjects. 
Results are expressed as a mean ± SEM of four independent experiments. (* p<0,05; ** 
p<0,02; *** p<0,002; t-test).  
 
 
DUSP6 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
12-15 L279X 0,33 0,07 0,001 
9-15 L359X 0,20 0,06 8,90E-05 
1121-14 R443X 9,63 1,53 0,002 
ERK1 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
12-15 L279X 0,83 0,33 0,373 
9-15 L359X 1,13 0,5 6,39E-01 
1121-14 R443X 0,54 0,11 0,003 
PEA3 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
12-15 L279X 0,98 0,39 0,935 
9-15 L359X 0,18 0,09 1,00E-03 
1121-14 R443X 0,96 0,06 0,275 
C 
D 
B 
A 
E 
F 
Missense mutation C-terminal 
 
 
 
 
 
 
Figure 111: (B,D,F) Real time PCR analysis performed in patients with missense 
mutation in the C-terminal part of the IDS gene, using DUSP6, ERK1 and PEA3 primers. 
The results were compared to unaffected control subjects. (A,C,E) Graphic representation 
of DUSP6, ERK1 and PEA3 expression in patients samples compared to unaffected 
DUSP6 
Sample Mutation Mean Standard 
deviation 
p-
value 
Control / 1 / / 
H148 C422R 1 0,00 0,00 4,49E-09 
H162 C422R 2 0,00 0,00 2,72E-08 
f24 P467L 0,63 0,13 0,012 
H8 R468Q 1 5,69 0,52 0,001 
13-15 R468Q 2 1,67 0,55 0,031 
1124-14 R468Q 3 1,68 0,57 0,033 
1122-14 R468Q 4 0,05 0,00 2,60E-08 
ERK1 
Sample Mutation Mean Standard deviation p-value 
Control / 1 / / 
H148 C422R 1 0,13 0,04 7,98E-04 
H162 C422R 2 0,30 0,05 1,51E-03 
f24 P467L 0,92 0,22 0,527 
H8 R468Q 1 1,63 0,26 0,016 
13-15 R468Q 2 2,7 0,59 0,010 
1124-14 R468Q 3 1,71 0,4 0,039 
1122-14 R468Q 4 0,78 0,10 2,40E-02 
PEA3 
Sample Mutation Mean Standard deviation 
p-
value 
Control / 1 / / 
H148 C422R 1 0,42 0,15 2,24E-02 
H162 C422R 2 1,50 0,32 2,50E-02 
f24 P467L 1,98 0,27 0,005 
H8 R468Q 1 4,78 0,48 0,001 
13-15 R468Q 2 0,97 0,21 0,800 
1124-14 R468Q 3 1,84 0,4 0,025 
1122-14 R468Q 4 0,12 0,02 6,30E-06 
E 
D C 
F 
A 
B 
subjects. Results are expressed as a mean ± SEM of four independent experiments. (* 
p<0,05; ** p<0,02; *** p<0,002; t-test). 
 
I examined the rate of dysregulation (down regulation, no change or up regulation) of 
each FGF signaling-marker (DUSP6, ERK1 and PEA3) in patient samples.  
DUSP6 is down regulated in the 67% of patients, up regulated in the 28% and has no 
change in its expression in the 5% of patients (Fig. 112). 
ERK1 is down regulated in the 57% of patients, up regulated in the 24% and has no 
change in its expression in the 19% of patients (Fig. 113). 
PEA3 is down regulated in the 38% of patients, up regulated in the 48% and has no 
change in its expression in the 14% of patients (Fig. 114). 
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Figure 112: Percentage of 
DUSP6 dysregulation (down 
regulation, up regulation or no 
change) in patients. 
Figure 113: Percentage of ERK1 
dysregulation (down regulation, 
up regulation or no change) in 
patients. 
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Figure 114: Percentage of PEA3 
dysregulation (down regulation, 
up regulation or no change) in 
patients. 
 
 
5 DISCUSSION 
 
Traditionally, the pathogenesis of Mucopolysaccharidosis type II has been attributed 
exclusively to the systemic accumulation of undegraded glycosaminoglycans and the 
consequent alterations in cellular processes. 
However, considering the clinical heterogeneity of  patients manifestations, this might be 
a simplistic view of a complex etiology. There is no correlation between enzymatic 
activity, that in patients is completely or almost completely depleted, and the degree of 
phenotypic severity. Moreover, patients with the same mutation may display different 
pathological manifestations (Martin et al., 2008). Despite IDS is an ubiquitously 
expressed enzyme, there is no correlation between MPSII severity and the extent of 
GAGs accumulation, organ involvement and tissue response to therapeutic treatments. 
Moreover, the mouse model of another mucopolysaccharidosis, MPS I, displays a 
progressive worsening of symptoms irrespective of tissutal GAGs accumulation (Heppner 
et al., 2015).  
These observations led my scientific group to hypothesize that alternative pathological 
mechanisms may occur in Hunter syndrome, together with GAGs storage.  
Mucopolysaccharidosis type II is characterized by the involvement of many organs in 
which different cascades of molecular alterations may occur. To simplify the 
investigation of candidate molecular mechanisms underlying MPSII, I focused my 
research on the skeletal system.  
It has been already shown in other MPSs that altered signaling pathways may be 
responsible for the skeletal manifestations: the MPS VI mouse model displays an 
(Simonaro et al., 2005), and altered FGF 
signaling regulation has been detected in MPS I chondrocytes and MPS I mouse bones 
(Kingma et al., 2016). 
alterations may occur. In the MPSI mouse model it has been demonstrated that alterations 
of  skeletal development appear very early, before any histological change (Heppner et 
al., 2015). Moreover, ERT is completely unsuccessful in treating Hunter syndrome-
related bone manifestations (Morini et al.,2010), suggesting that the only iduronate 2-
sulfatase replacement is not sufficient to restore normal skeletal development and 
homeostasis.  
In this work it has been hypothesized that IDS, beyond its GAGs catabolic role inside 
lysosomes, may have other molecular functions. It has been already demonstrated that 
this enzyme is an important regulator of early developmental stages and that it controls 
the osteogenic process (Moro et al., 2010; Mandal et al., 2013).  
For the comprehension of the molecular pathogenesis of Mucopolysaccharidosis type II, I 
took advantage of the zebrafish model, which allows to rapidly analyze signaling 
pathways and bone ossification defect in different life stages (Hammond & Moro, 2012).  
Using the fish model, I first demonstrated that the IDS enzyme is highly expressed in 
bone regions with high osteogenic activity. In zebrafish the opercle, brachiostegal ray and 
ceratobranchial arches are neural crest-derived bones, while the cleithrum is of 
mesodermal origin (Kague et al., 2012). Immunohistochemical analysis at 5dpf showed 
that the IDS protein is particularly enriched in bones of neural crest origin, such as the 
opercle and brachiostegal ray, while it is weakly localized in the cleithrum.  
I created different IDS loss of function zebrafish models using the morpholino technology 
and the Crispr/Cas9 technique. These animal models have been shown to be good to 
evaluate MPSII pathogenesis, because they display some typical Hunter patient  
manifestations  such  as  hepatomegaly and defects in chondrogenesis and  osteogenesis. 
Using a translation initiation blocking morpholino for the fish Ids orthologue, I showed 
that fish morphants display an early down regulation of sox10 expression, which is a 
marker of migrating cranial neural crest cells. The decrease of Sox10 was in turn 
associated with a dysregulation of bone markers expression together with cartilage and 
bone formation defects. The impaired expression of sox10 and bone markers, appeared 
before any evident massive accumulation of GAGs, suggesting that other molecular 
mechanisms may have been implicated since early stages in the pathogenic process.   
Interestingly, I found an up regulation of the FGF signaling in Ids-KD fish at 2dpf 
compared to age-matched controls, and this dysregulation was maintained during 
postnatal stages. 
FGF signaling is a pathway involved in many developmental processes, including the 
skeletal embryonic development and postnatal growth (Ornitz et al., 2002). Therefore, I 
hypothesized that Ids deficiency may affect FGF signaling during early stages of 
development, thus leading to an impaired expression of genes involved in bone 
formation. 
FGF signaling induces cranial neural crest (NCC) differentiation and regulates the 
expression and function of the Sox10 transcription factor (Dravis et al., 2015; Teven et 
al., 2014). Sox10 is an important regulator of migrating NCCs, that differentiate into bone 
and cartilage, and it has been found to activate the Col2a1 gene transcription (Suzuki et 
al., 2006). In Ids-KD morphant Sox10 appears to be down-regulated and morphant fish 
display defective runx2b and collagenX expression, in neural crest-derived bones 
(opercle, brachiostegal ray, ceratobranchial arch). Moreover, FGF signaling is essential 
during early stages of endochondral and intramembranous ossification (Ornitz et al., 
2002). In agreement with this, morphant fish showing alterations of the FGF pathway 
exhibited severe defects in chondrogenesis and osteogenesis. 
To address the potential involvement of the FGF signaling in Ids loss of function models, 
I tested also a splicing site-blocking morpholino targeting a splice acceptor site of the ids 
exon2. While confocal microscopy and in situ hybridization analysis showed a down 
regulation of the FGF pathway similar results were not detected by quantitative real time 
PCR analysis. This discrepancy may be due to the fact that both confocal and in situ 
hybridization analysis allow the detection of tissue-specific differences of protein 
localization and gene expression, respectively. Indeed real time PCR analysis is generally 
performed on whole fish lysates.  
In contrast to the up regulation of the FGF signaling detected in fish treated with the 
translation initiation-blocking morpholino, morphants generated by the Ids splicing site-
blocking morpholino showed a mild FGF down-regulation. This further discrepancy may 
be due to the different targeting of the morpholinos: while the translation initiation-
blocking one abrogates Ids synthesis from the ATG codon, the splicing site-blocking one 
leads to the generation of a truncated Ids peptide. It may be tempting to speculate that in 
some cases the complete abrogation of Ids function could trigger a boost of the FGF 
signaling, as a compensative mechanism. On the other hand, short Ids peptides, produced 
by premature stop codons, may act as dominant negative factors against the FGF 
pathway. 
Nonetheless, both morphant models are characterized by a partial enzymatic deficiency 
which does not reflect the complete lack of IDS activity observed in Hunter patients. 
Moreover all morpholinos suffer from temporally-restricted activity, thus hampering 
analysis at late life stages.  
To address these issues, by the Crispr/Cas9 technology I generated a stable zebrafish 
mutant which exhibited a complete loss of Ids activity.  
Ids-KO fish at early stages of development showed a characteristic rapid bone 
mineralization process, which was associated with increased expression of bone-related 
markers up to 7dpf.  
In mutant fish, the FGF pathway was shown to be down regulated, in agreement with the 
results obtained with the splicing-blocking morpholino. Since in the mutant a premature 
stop codon, due to an upstream deletion of five nucleotides was produced, the above 
mentioned hypothesis of a dominant-negative effect of a truncated Ids protein on FGF 
signaling activity cannot be ruled out. 
Despite controversial studies describing the role of FGF signaling in bone formation, it 
has been already reported that reduced FGF signaling activity is associated with 
decreased proliferation of osteoprogenitor cells, while enhanced FGF signaling, is 
associated with increased osteoblast differentiation and apoptosis (Su et al., 2014; Ornitz 
& Marie, 2015).  
Thus, the impaired FGF signaling-related osteogenic and chondrogenic process detected 
in the generated morphant and mutant Ids loss of function fish models represents a 
potential intriguing causative mechanism underlying the skeletal defects observed in 
Hunter patients.  
To further support the results obtained with the fish models, I extended my investigation 
using an already established IDS knockout mouse model (Garcia et al., 2007). In 
particular, IDS-KO mice showed irregularly shaped Alcian blue-stained cranial sutures, 
suggesting a premature defective bone mineralization process. On the other hand, long 
bones of IDS-KO mice appeared normal at early stages of development, while at six 
months of age they start to become shorter when compared with age-matched WT mice. 
A detailed expression profile, revealed that IDS KO mice display a significant increase in 
the col2a1 expression and decrease of bone-related markers (collagen X and osteocalcin), 
already at postnatal stages, when GAGs storage is negligible. More interestingly, the 
reduced expression of bone-related markers was not associated with increased 
differentiation which was not related to an inflammatory process.  
When evaluating FGF signaling markers, I found a substantial down regulation of FGF-
related target genes, particularly in the epiphysis of long bones, supporting the evidence 
that secondary ossification centers appear more susceptible to the cell signaling defects.  
My observations are in agreement with the well-established role of FGF signaling in 
cranial suture premature closure and maintenance of proliferating osteogenic cells in the 
epiphyseal growth plate (Ornitz et al, 2002; Ornitz et al., 2015; Teven et al., 2014). It 
remains to be elucidated which of the different FGF ligands and receptors may be more 
affected in the long bones of IDS KO mice. 
The use of different animal models confirmed the involvement of FGF signaling in the 
defective skeletal development occurring as a consequence of IDS loss of function. 
According to different variables, including the type of animal model, the degree of 
enzymatic dysfunction, the stage of development and analyzed tissue, a different FGF 
pathway dysregulation has been detected. In Hunter disease more than 300 different 
mutations have been so far characterized in the IDS gene (www.hgmd.org). Therefore, the 
animal models I used, do not perfectly resemble the wide spectrum of genetic alterations 
underlying Hunter syndrome. Nonetheless, a convincing evidence of a direct link between 
IDS loss of function and FGF pathway deregulation might come from the analysis of 
patients fibroblasts harboring different IDS mutations. For this reason, I decided to 
analyze the expression of FGF pathway-related markers in isolated fibroblasts of  a 
selected group of Hunter patients affected by well-defined mutations. All patients were 
characterized by different phenotypes (mild, intermediate or severe form) which were 
independent from the type and position of mutations in the IDS gene.  
Despite heterogeneous results, all patients with a mild form of MPSII showed a general 
down regulation of FGF signaling markers. 
In particular, most patients displayed a down regulation of DUSP6 (67%) and 
ERK1(57%) markers when compared with healthy controls. DUSP6 is a downstream 
target of FGF signaling and the activation of its transcription is regulated through the 
RAS/MAPK pathway in which ERK1 is a transducer (Znosko et al., 2010). Only 33% of 
the patients exhibited  a down regulation of PEA3, which is a downstream target of FGF 
signaling and mediate the transcriptional response of the FGF pathway, activating directly 
DUSP6 expression (Znosko et al., 2010). This result may suggest that other pathways 
may be implicated in the regulation of PEA3 expression downstream to IDS loss of 
function. 
Nevertheless, although the number of patients so far examined is limited, it might be 
plausible to conclude that at least in a significant proportion of Hunter patients a direct 
link between IDS deficit and FGF pathway deregulation does exist. 
Which mechanisms may underlie the FGF pathway impairment due to IDS dysfunction 
remain to be clarified. It is possible that mutations altering lysosomal function may affect 
the endosomal/lysosomal system which controls the recycling of FGF receptors, or the 
transport of extracellular and membrane FGF pathway-associated proteins. Alternatively, 
since Iduronate 2-sulfatase participates to the catabolism of heparan and dermatan sulfate, 
alterations of its enzymatic activity may negatively impact on the amount, distribution 
and type of extracellular matrix components. In agreement with the latter hypothesis, 
other  lysosomal storage disorders showed an impaired extracellular matrix remodeling 
(Ballabio & Gieselmann, 2009; Heppner et al, 2015). Since the extracellular matrix plays 
key roles in cell signaling modulation, its structural and functional impairment may affect 
the binding and diffusion of growth factors and signaling ligands. Moreover extracellular 
matrix components can enhance the interaction between cell-specific receptors and 
ligands or participate in signal transduction by directly activating cell signaling (Lu et al., 
2011). 
In particular, the ECM has been shown to have an important role in the regulation of FGF 
signaling activation, since heparan sulfate binding to FGF receptors and ligands is 
necessary to trigger the downstream pathway (Tumova et al., 2000). Alterations of GAGs 
distribution in the ECM may cause dysregulation of cell signaling pathways, including 
FGF signaling (Kingma et al., 2016).  
Other mechanisms independent from the IDS enzymatic activity deficiency may be 
evoked. Intriguingly, as different mutations predicted to produce alternative IDS 
conformational structures have been shown to differently regulate the FGF pathway, it 
might be possible that the IDS enzyme itself may directly interact with key FGF-related 
cell signaling molecules.  
In conclusion, this work showed that cell signaling alterations, earlier than substrate 
accumulation can be responsible for the skeletal manifestations in MPSII. A more 
complete knowledge of Hunter syndrome pathogenesis could contribute to the 
identification of novel therapies for the targeted treatment of MPSII bone defects. 
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